continu
epidemiolog
surveil
exist
emerg
virus
associ
disord
gain
import
light
abil
caus
unpredict
outbreak
result
increas
travel
vaccin
choic
steadili
grow
age
popul
close
surveil
outbreak
herd
immun
also
forefront
even
industri
countri
previous
erad
virus
risk
reemerg
due
instanc
strain
recombin
contract
viral
vector
geographi
potenti
use
agent
bioterror
great
need
ration
design
current
futur
vaccin
target
virus
strong
focu
vaccin
target
adapt
immun
effector
memori
cell
gold
standard
immun
confer
longliv
protect
wide
varieti
pathogen
malign
review
virus
histor
caus
larg
outbreak
sever
lethal
disord
includ
respiratori
gastric
skin
hepat
neurolog
hemorrhag
fever
observ
trend
vaccinolog
viral
disord
describ
viral
genet
replic
transmiss
tropism
hostimmun
evas
strategi
epidemiolog
health
risk
associ
syndrom
focu
immun
gener
natur
infect
vaccin
steadi
shift
confer
vaccin
immunogen
observ
quantifi
activ
prolifer
longliv
effector
memori
cell
subset
promin
biomark
longterm
immun
virus
associ
disord
caus
high
morbid
mortal
rate
world
forev
chang
introduct
vaccin
smallpox
late
time
protect
first
individu
first
demonstr
vaccin
could
success
erad
virus
caus
disord
diseas
even
lethal
still
potenti
crippl
surviv
popul
surround
geograph
economi
sinc
time
occurr
epidem
outbreak
lower
risk
follow
introduct
massiv
vaccin
program
abl
induc
immun
system
target
virus
caus
sever
disord
affect
distinct
geograph
locat
mani
epidemiolog
report
demonstr
longterm
efficaci
viral
control
popul
outbreak
exist
emerg
viral
diseas
disord
vari
wide
durat
frequenc
across
geograph
popul
predict
annual
other
may
see
decad
outbreak
therefor
drive
continu
epidemiolog
surveil
associ
infecti
disord
develop
implement
target
vaccin
develop
immunemonitor
strategi
measur
vaccin
effici
target
popul
despit
vaccinationmedi
protect
numer
nation
document
complet
erad
caus
agent
viral
disord
endem
popul
threat
reemerg
pandem
proport
agent
threat
viru
reemerg
caus
contemporari
choic
made
vaccin
children
strain
recombin
viral
spread
popul
worldtravel
migrant
climat
chang
caus
redistribut
viral
vector
potenti
use
agent
act
bioterror
war
upheav
deplet
vaccin
stock
requir
protect
pandem
factor
includ
increas
age
global
popul
increas
number
immunocompromis
individualsd
factor
strongli
support
mainten
herd
immun
exist
virus
despit
lower
incid
outbreak
industri
countri
event
reemerg
previous
erad
virus
acquisit
increas
pathogen
exist
viral
strain
urgent
need
vaccin
develop
strategi
rapidli
effect
arrest
global
spread
import
advanc
continu
made
vaccin
develop
strategi
toward
control
virus
associ
disord
vaccin
design
modifi
use
attenu
virus
use
precis
viral
protein
subunit
specif
target
cell
histor
vaccin
immunogen
document
measur
serum
immunoglobulin
ig
class
antigenspecif
antibodi
produc
humor
immun
recent
quantif
cellular
compon
innat
immun
interfac
innat
adapt
immun
made
addit
precis
measur
adapt
immun
longterm
protect
achiev
adapt
immun
quantifi
measur
level
circul
cytokin
along
specif
phenotyp
profil
effector
memori
antigenspecif
cell
though
humor
cellular
arm
immun
integr
link
initi
induct
immun
pathogen
becom
disconnect
develop
patholog
due
individu
need
surviv
factor
unequ
declin
immun
function
differenti
cellular
lifespan
loss
correl
memori
cell
neutral
antibodi
respons
vari
accord
differ
virus
suggest
independ
time
cours
measur
separ
immun
respons
requir
time
adequ
record
biomark
natur
infect
vaccin
efficaci
suggest
cell
statu
may
crucial
measur
confer
longterm
immun
standpoint
fundament
clinic
research
becom
establish
target
induct
specif
pathogenand
tumorclear
effector
memori
cell
subset
endgam
armor
toward
longterm
human
surviv
infecti
diseas
cancer
chapter
provid
overview
virus
histor
caus
sever
lethal
disord
includ
respiratori
gastric
skin
hepat
neurolog
hemorrhag
type
featur
virus
associ
disord
herein
describ
includ
viral
genet
replic
cycl
transmiss
modal
cell
organ
tropism
hostimmun
evas
strategi
associ
viral
disord
diseas
epidemiolog
also
report
wellaccept
import
document
instanc
viral
control
cell
current
avail
success
vaccin
record
measur
vaccin
immunogen
focu
quantif
vaccineinduc
effector
memori
cellemedi
immun
repres
gold
standard
success
vaccin
advanc
vaccinolog
investig
biolog
cell
current
forefront
mani
research
field
examin
variou
disord
diseas
malign
formerli
consid
control
immun
although
mani
viral
infect
limit
upper
respiratori
tract
lower
respiratori
tract
infect
lrti
predominantli
caus
enorm
diseas
burden
children
immunocompromis
adult
suffer
human
immunodefici
viru
hiv
infect
patient
receiv
stem
cell
solid
organ
transplant
immunosuppress
therapi
administ
henrickson
et
al
pavia
kim
et
al
acut
lower
respiratori
ill
alri
major
caus
morbid
mortal
account
approxim
million
death
global
per
year
black
et
al
frequent
overlap
lrti
syndrom
includ
bronchiol
asthma
exacerb
wheez
croup
pneumonia
although
certain
specif
syndrom
precis
associ
infect
specif
virus
syndrom
overlap
complic
diagnosi
numer
virus
quit
often
difficulti
differenti
viral
bacteri
pneumonia
symptom
also
result
antibiot
mistakenli
prescrib
viral
disord
sever
virus
normal
howev
consid
primarili
respons
lrti
begin
upper
respiratori
tract
infect
commonli
caus
respiratori
virus
typic
spread
persontoperson
contact
infect
respiratori
droplet
includ
respiratori
syncyti
viru
rsv
epidem
influenza
b
avian
influenza
virus
iav
parainfluenza
virus
adenoviru
human
metapneumoviru
hmpv
sever
acut
respiratori
syndrom
coronaviru
human
coronavirus
rhinovirus
bocavirus
pavia
mahoni
nichol
et
al
tabl
current
vaccin
human
influenza
virus
human
parainfluenza
virus
hpiv
adenovirus
caus
upper
lower
respiratori
infect
use
control
infect
result
propag
morbid
symptom
deriv
human
influenza
virus
make
three
five
genera
famili
orthomyxovirida
classifi
b
c
type
base
highli
conserv
matrix
protein
membran
matrix
protein
nucleoprotein
np
type
influenza
virus
subsubtyp
antigen
hemagglutinin
ha
neuraminidas
na
surfac
glycoprotein
gp
antigen
drift
caus
point
mutat
ha
na
recombin
ha
gene
result
gener
new
strain
escap
preexist
immun
caus
predict
circul
strain
difficult
antigen
mismatch
exist
vaccin
approxim
ha
na
subtyp
influenza
document
aquat
bird
repres
natur
host
ie
vector
influenza
subtyp
cocircul
season
influenza
b
virus
infect
human
via
two
distinct
season
cocircul
lineag
type
c
influenza
virus
rare
document
infect
human
pig
berlanda
scorza
et
al
influenza
virus
caus
acut
upper
lower
respiratori
infect
due
rapid
unpredict
genet
drift
repres
like
pathogen
caus
human
pandem
annual
human
influenza
virus
potenti
caus
million
case
sever
ill
associ
death
worldwid
whoinfluenza
season
caus
great
econom
burden
four
influenza
pandem
occur
past
centuri
consequ
variant
pales
sinc
recent
outbreak
estim
peopl
global
succumb
variant
swine
origin
dawood
et
al
epitheli
cell
infect
influenza
viru
produc
inflammatori
cytokin
act
chemoattract
home
macrophag
dendrit
cell
dc
dc
take
influenza
viral
particl
trigger
matur
pursuant
migrat
lymph
initi
antigenspecif
cell
matur
influenzaspecif
effector
cell
enter
respiratori
tract
counteract
viral
titr
cytokin
express
direct
lysi
infect
cell
activ
effector
cytotox
cell
ctl
repres
main
constitu
respons
releas
perforin
granzym
engag
tumor
necrosi
factor
tnf
receptor
spitael
et
al
influenzaspecif
helper
cell
act
directli
indirectli
viral
clearanc
primarili
produc
cytokin
induc
function
b
cell
cell
also
report
directli
elimin
infect
cell
topham
doherti
hua
et
al
preexist
cell
immun
yet
demonstr
prevent
infect
occur
hypothes
result
loss
granzym
express
memori
cell
popul
iavspecif
cell
still
importantli
correl
control
spread
recoveri
healthi
popul
grant
et
al
current
administ
influenza
vaccin
inactiv
iv
trival
tiv
quadrival
formul
contain
equal
amount
ha
two
influenza
strain
one
two
influenza
b
strain
yamagata
victoria
lineag
deriv
virus
typic
grown
fertil
chicken
egg
mainli
focus
elicit
strainmatch
humor
immun
responsedrequir
yearli
updatesdand
unabl
provid
protect
vaccin
individu
requir
memori
cell
immun
longterm
protect
influenza
viru
promot
develop
vaccin
elicit
humor
cellular
immun
strategi
expect
overcom
inadequaci
current
vaccin
influenza
virus
spitael
et
al
broad
interest
develop
univers
influenza
vaccin
consid
holi
grail
influenza
vaccin
research
approach
develop
use
virusinfect
cellkil
antibodi
produc
antivir
environ
term
antibodydepend
cellular
cytotox
adcc
mediat
antibodi
predict
link
innat
adapt
immun
respons
becom
possibl
due
new
technolog
rapid
isol
character
monoclon
antibodi
target
conserv
region
influenza
viru
review
jegaskanda
et
al
approach
postul
work
part
report
iavspecif
cell
promot
viral
clearanc
absenc
neutral
antibodi
also
mediat
crossreact
immun
distinct
iav
drive
rapid
recoveri
sever
influenza
disord
grant
et
al
induct
infectionpermiss
immun
protect
allow
virusinduc
crossreact
immun
respons
vaccin
target
conserv
ectodomain
deliv
kind
nonneutr
immun
sinc
antibodi
reli
fc
receptor
innat
immun
compon
el
bakkouri
et
al
antagon
antibodi
inhibit
na
activ
repres
anoth
promis
strategi
block
viral
entri
elicit
steril
immun
contribut
immun
viru
possess
similar
na
type
wan
et
al
also
progress
made
develop
recombin
celleinduc
vaccin
advanc
version
strategi
demonstr
modifi
vaccinia
ankara
mva
virus
express
influenza
viru
np
antigen
berthoud
et
al
vaccin
individu
demonstr
increas
interferongamma
ifng
express
cell
increas
protect
influenza
infect
antrobu
et
al
powel
et
al
coadministr
mvabas
vaccin
tiv
formul
result
increas
influenza
strainespecif
antibodi
respons
gener
memori
cell
recogn
rang
influenza
subtyp
antrobu
et
al
addit
research
demonstr
product
antigenspecif
cell
respons
use
altern
primeboost
regiment
combin
vaccin
regimen
employ
recombin
replicationdefici
adenoviru
mva
express
iav
np
matrix
protein
lamb
et
al
qualiti
clonal
cell
receptor
tcr
characterist
influenzaspecif
cell
addit
silico
predict
peptidebas
approach
pool
minim
iav
epitop
investig
induct
cellular
immun
recognit
cell
review
grant
et
al
hpiv
envelop
negativesens
rna
genom
virus
nm
belong
larg
rapidli
grow
paramyxovirida
famili
caus
signific
human
veterinari
disord
henrickson
hpiv
divid
serotyp
repres
common
etiolog
agent
associ
diseas
repres
common
caus
agent
respiratori
ill
pediatr
geriatr
immunocompromis
popul
schmidt
et
al
hpiv
common
caus
acut
respiratori
ill
throughout
stage
human
life
schomack
et
al
caus
acut
respiratori
infect
children
cooney
et
al
second
human
respiratori
syncyti
viru
hpiv
major
contributor
hospit
due
alri
global
pneumonia
mortal
young
children
children
seroposit
hpiv
age
year
murphi
weinberg
et
al
hpiv
infect
induc
potent
humor
cellular
immun
respons
includ
innat
immun
respons
local
system
igg
iga
respons
adapt
cell
respons
gitlin
et
al
hou
et
al
though
cellular
respons
restrict
hpiv
replic
dynam
clear
primari
infect
neutral
antibodi
viru
envelop
hemagglutininneuraminidas
hn
fusion
f
gp
requir
earli
infect
suzuki
et
al
zhang
et
al
confer
longterm
protect
hpivrel
disord
murphi
sprigg
et
al
schmidt
et
al
current
vaccin
protect
human
hpiv
infect
progress
develop
hpiv
vaccin
use
revers
genet
serotyp
gener
sever
liveattenu
intranas
hpiv
vaccin
evalu
adult
children
two
well
toler
pediatr
popul
schmidt
et
al
ongo
pediatr
trial
test
liveattenu
hpiv
vaccin
predict
replic
upper
respiratori
tract
infant
induc
full
spectrum
humor
cellular
immun
respons
karron
et
al
heterolog
ie
jennerian
vaccin
design
strategi
use
sendai
viru
sev
control
infect
hpiv
rsv
discuss
follow
section
human
respiratori
syncyti
viru
rsv
type
b
found
within
genu
orthopneumoviru
famili
pneumovirida
order
mononegaviral
rsv
envelop
spheric
viru
nm
diamet
reach
sever
micromet
length
gower
et
al
negativesens
rna
genom
encod
outer
structur
np
polymeras
ns
transmembran
regulatori
protein
griffith
et
al
rsv
major
caus
alri
result
numer
pediatr
hospit
global
year
age
children
expos
risk
develop
lifethreaten
bronchiol
pneumonia
glezen
et
al
hall
et
al
henrickson
infant
hospit
due
rsv
infect
unit
state
mark
million
episod
rsvassoci
alri
children
global
repres
least
million
case
result
hospit
approxim
associ
death
per
year
nair
et
al
balanc
adapt
immun
ctl
neutral
antibodi
humor
immun
respons
mediat
protect
clearanc
rsv
infect
griffith
et
al
though
neutrophil
highest
proport
leukocyt
found
airway
infect
rsv
everard
et
al
despit
observ
natur
killer
nk
cell
first
attain
infect
airway
hussel
openshaw
helper
ctl
correl
earli
clearanc
rsvinfect
cell
anderson
et
al
infant
immunocompromis
popul
fatal
result
rsv
infect
associ
defici
cytotox
cell
hall
et
al
welliv
et
al
later
infect
increas
neutral
antibodi
prevent
reinfect
opson
viral
epitop
requir
rsv
entri
infect
rsv
clearanc
associ
rsvneutral
nasal
immunoglobulin
iga
mcintosh
et
al
recent
enhanc
rsv
clearanc
reduc
diseas
sever
associ
vaccineelicit
memori
cell
lee
et
al
memori
cell
mediat
protect
rsv
infect
absenc
antibodi
memori
cell
caus
mortal
via
system
proinflammatori
cytokin
storm
local
ifng
product
stoley
et
al
schmidt
et
al
recent
studi
howev
indic
cell
respons
may
major
determin
sever
rsvrelat
patholog
collin
melero
current
sever
recombin
rsv
subunit
vaccin
clinic
trial
includ
novavax
rsv
f
vaccin
repres
promis
candid
licens
rsv
f
subunit
target
vaccin
demonstr
elicit
express
circul
neutral
antibodi
rsv
glenn
et
al
toward
develop
futur
adapt
immunityinduc
rsv
vaccin
demonstr
transfer
airwayresid
cell
protect
rsv
suggest
lessen
burden
cellemedi
damag
airway
induct
lung
tissu
cell
focu
vaccin
develop
kinnear
et
al
recent
sev
use
compon
jennerian
vaccin
model
backbon
virus
caus
seriou
lower
respiratori
infect
lri
includ
hpiv
rsv
hmpv
sevbas
vaccin
proven
effect
toward
induc
b
cell
cell
immun
respons
protect
rsv
also
use
combin
vaccin
primeeboost
target
one
one
paramyxoviru
pathogen
russel
hurwitz
sev
attract
use
human
vaccin
murin
pathogen
unabl
infect
human
bouss
et
al
therefor
requir
attenu
never
revert
human
pathogen
phenotyp
schickli
et
al
anoth
import
featur
support
use
sev
panviru
vaccin
agent
stem
abil
grow
transient
mammalian
cell
accommod
endogen
express
antigen
posttransl
modif
match
target
antigen
neutral
epitop
henrickson
et
al
endogen
express
antigen
ensur
robust
activ
cell
abl
destroy
antigenproduc
cell
termin
viru
amplif
york
rock
russel
hurwitz
murin
studi
sev
could
elicit
rapid
durabl
respiratori
mucosa
system
hpivspecif
b
cell
cell
respons
seali
et
al
rudraraju
et
al
clinic
test
human
popul
infect
rsv
hpiv
underway
adderson
et
al
full
review
current
develop
antivir
compound
vaccin
candid
test
rsv
see
costello
et
al
adenoviru
classif
epidemiolog
immunolog
vaccinolog
human
adenovirus
hadv
classifi
mastadenoviru
genu
contain
seven
known
hadv
speci
hadva
hadvg
least
uniqu
known
human
serotyp
buckwalt
et
al
adenovirus
nonenvelop
doublestrand
dna
virus
rang
nm
diamet
compos
protein
capsid
np
core
intern
protein
dna
homolog
hadv
subgroup
rang
wall
et
al
hadv
infect
rare
caus
seriou
fatal
ill
immunocompet
individu
may
caus
sever
diseas
immunocompromis
pediatr
geriatr
popul
lynch
et
al
clinic
diseas
symptom
associ
hadv
depend
hadv
genotyp
least
recogn
assign
subgroup
g
clinic
symptom
includ
fever
rhinorrhea
pharyng
conjunct
gastroenter
bronchiti
pneumonia
acut
hemorrhag
cystiti
meningoenceph
lynch
et
al
recombin
hadv
larg
respons
outbreak
acut
febril
respiratori
diseas
immunocompet
militari
recruit
serotyp
type
document
account
approxim
respiratori
ill
hilleman
et
al
dud
et
al
associ
frequent
occur
disord
includ
upper
lower
respiratori
ill
gastroenter
hepat
keratoconjunct
meningoenceph
cystiti
myocard
immunocompet
popul
review
lion
adenovirus
endem
pediatr
popul
echavarria
incid
adenoviru
infect
peak
infant
children
global
respiratori
tract
infect
pediatr
patient
ascrib
hadv
ghebremedhin
recent
reemerg
type
hadv
caus
fatal
outbreak
due
sever
pneumonia
syndrom
children
highdens
popul
immun
respons
adenoviru
infect
depend
primari
site
inocul
method
transmiss
viral
serotyp
secretori
ig
antibodi
statu
infect
host
iga
present
respiratori
tract
earli
follow
infect
present
serum
nasal
secret
later
time
point
review
wall
et
al
histopatholog
chang
result
infect
divid
two
phase
first
phase
immun
histopatholog
predominantli
involv
nonspecif
cytokinemedi
inflammatori
recruit
monocyt
macrophag
second
phase
involv
cell
infiltr
princ
et
al
cellemedi
immun
believ
requir
hadv
recoveri
acut
infect
individu
lack
adapt
immun
found
elev
risk
infect
cell
primari
mediat
respons
respiratori
virus
rel
littl
contribut
cell
woodland
et
al
howev
follow
adenoviru
exposur
cell
shown
respons
increas
prolifer
statu
peripher
blood
mononuclear
cell
pbmc
cell
repres
major
ctl
subset
produc
recogn
conserv
antigen
across
adenoviru
serotyp
flomenberg
et
al
regn
et
al
adenovirus
howev
evolv
sever
hostevas
strategi
includ
inhibit
apoptosi
respons
ifng
tnfa
major
histocompat
complex
mhc
class
express
mahr
good
wold
et
al
wold
et
al
live
oral
adenoviru
vaccin
licens
activ
immun
toward
prevent
febril
acut
respiratori
diseas
militari
popul
initi
reduc
adenovirusassoci
respiratori
ill
fivefold
dud
et
al
vaccin
stock
deplet
associ
epidem
led
manufactur
anoth
vaccin
dent
adenovirusassoci
diseas
burden
approxim
among
recruit
within
first
year
introduct
radin
et
al
oral
lyophil
vaccin
replic
asymptomat
gut
induc
humor
cellmedi
immun
confer
longlast
protect
infect
berg
et
al
due
abil
induc
potent
transgen
productspecif
tand
bcell
respons
adenoviru
vector
explor
use
vaccin
carrier
varieti
mani
pathogen
chen
et
al
harro
et
al
hill
et
al
radosev
et
al
alri
respiratori
virus
major
caus
morbid
mortal
account
million
death
global
year
predominantli
result
human
transmiss
viru
contain
respiratori
droplet
licens
vaccin
use
sever
virus
caus
sever
often
lethal
associ
disord
influenza
border
caus
great
econom
burden
make
promin
intern
concern
rapid
unpredict
genet
drift
caus
human
pandem
annual
potenti
caus
million
infect
death
worldwid
influenza
vaccinolog
requir
constant
yearli
updat
stimul
interest
develop
univers
cell
vaccin
elicit
humor
cellular
immun
wherebi
influenzaspecif
memori
cell
respons
rang
influenza
subtyp
could
induc
clear
infect
absenc
neutral
antibodi
rsv
caus
million
alri
children
annual
result
million
hospit
almost
death
per
year
rsv
clear
balanc
adapt
immun
ctl
humor
neutral
antibodi
respons
correl
highli
helper
ctl
natur
infect
memori
cell
follow
vaccin
research
endeavour
target
strengthen
specif
induct
lung
tissu
rsv
target
cell
second
rsv
hpiv
caus
mani
ariand
lriassoci
mortal
children
hpiv
induc
potent
humor
innat
adapt
cell
respons
abl
restrict
replic
neutral
antibodi
confer
longterm
protect
associ
disord
hadv
infect
immunocompet
immunocompromis
human
shown
caus
respiratori
disord
hospit
militari
personnel
despit
evolv
convolut
hostevas
strategi
adapt
cell
immun
hadv
start
earli
diseas
phase
key
recoveri
acut
natur
infect
greatest
contribut
cytotox
cell
requir
stimul
cell
expans
vaccin
hadv
induc
humor
adapt
immun
includ
potent
transgen
virusspecif
tand
bcell
respons
confer
longterm
protect
success
hadv
vaccinolog
influenc
explor
adenoviru
vector
target
carrier
vaccin
numer
pathogen
diarrheal
disord
remain
lead
caus
morbid
mortal
worldwid
list
top
five
caus
death
worldwid
associ
global
estim
million
death
per
year
review
clark
mckendrick
major
gastric
infect
viral
origin
viral
gastroenter
one
common
ill
age
group
import
caus
morbid
industri
countri
chang
et
al
human
risk
viral
gastroenter
unit
state
alon
least
one
per
individu
per
year
adult
children
hospit
record
associ
mortal
per
year
mead
et
al
mount
et
al
sever
virus
respons
viral
gastroenter
transmiss
typic
occur
persontoperson
oralfec
rout
virus
commonli
caus
gastroenter
includ
rotaviru
rv
caus
seriou
gastric
disord
noroviru
astroviru
adenoviru
coronaviruslik
agent
tabl
rv
classifi
genu
within
famili
reovirida
nonenvelop
virus
measur
nm
diamet
inner
outer
capsid
surround
core
contain
doublestrand
rna
viral
genom
encod
viral
capsid
outer
capsid
protein
mediat
viru
attach
cell
bishop
et
al
nonstructur
protein
review
desselberg
rv
classifi
seven
serotyp
aeg
base
antigen
properti
inner
capsid
protein
subtyp
aec
repres
human
pathogen
subclassifi
serotyp
within
group
basi
differ
outer
capsid
composit
anderson
weber
wilhelmi
et
al
diarrhea
major
caus
death
among
children
global
liu
et
al
rv
lead
caus
sever
diarrhea
global
caus
estim
death
develop
countri
million
pediatr
patient
hospit
parashar
et
al
rv
also
repres
signific
caus
diseas
industri
countri
greater
number
hospit
admiss
report
rel
develop
countri
chang
et
al
though
group
rv
caus
major
endem
infect
also
lead
signific
outbreak
infant
geriatr
popul
villena
et
al
marshal
et
al
group
b
rv
less
common
also
lead
outbreak
epidem
sanekata
et
al
ahm
et
al
wherea
group
c
rv
less
often
observ
caus
sporad
diseas
exist
g
eight
p
rv
group
serotyp
p
kostouro
et
al
clark
mckendrick
studi
cell
respons
rv
infect
human
report
healthi
adult
children
circul
rvspecif
cell
approxim
cell
express
intestin
home
receptor
circul
cell
secret
ifng
interleukin
il
makela
et
al
offit
et
al
yasukawa
et
al
rott
et
al
parra
et
al
frequenc
circul
ifng
rv
cell
compar
specif
mucos
respiratori
virus
mesa
et
al
often
possess
profil
termin
differenti
effector
cell
usual
associ
unabl
provid
longterm
immun
parra
et
al
yen
et
al
case
natur
neonat
rv
infect
fair
protect
rate
achiev
via
humor
immun
use
vaccin
though
unabl
protect
rv
reinfect
offer
protect
sever
associ
clinic
symptom
caus
patient
hospit
vaccin
offer
homotyp
heterotyp
immun
protect
often
correl
increas
rv
type
specif
igg
iga
antibodi
review
desselberg
huppertz
although
rv
vaccineeinduc
humor
immun
substanti
decreas
diseas
burden
vaccin
strategi
less
effect
difficult
implement
lowincom
countri
requir
patel
et
al
natur
rv
infect
vaccin
provid
nonsteril
immun
children
angel
et
al
lack
establish
longterm
immun
rv
caus
half
children
guardian
risk
becom
infect
present
sever
associ
disord
rodriguez
et
al
demonstr
rvspecif
rvt
cell
crucial
develop
overal
longterm
protect
immun
rv
franco
et
al
offit
et
al
inde
model
rv
infect
vaccineinduc
protect
immun
respons
depend
antivir
cytokin
product
direct
kill
rvinfect
cell
cell
b
cell
adapt
immun
subset
jiang
et
al
wen
et
al
addit
observ
gut
cell
may
becom
tolerogen
anerg
respons
rv
infect
stimul
cell
rv
antigen
presenc
pharmacolog
diacylglycerol
kinas
alpha
inhibitor
caus
increas
pbmc
frequenc
rv
antigenspecif
effector
cell
includ
tnfa
ifng
ifng
cell
parra
et
al
diarrheal
disord
caus
annual
million
death
worldwid
rv
lead
caus
sever
diarrhea
outbreak
infant
geriatr
popul
global
annual
estim
death
develop
countri
million
pediatr
hospit
immunocompet
individu
circul
rvspecif
ctl
compar
frequenc
elicit
respiratori
virus
termin
differenti
effector
profil
render
incap
confer
longterm
protect
reoccurr
associ
disord
rv
vaccineemedi
protect
sever
disord
humor
nonsteril
immun
unabl
protect
reinfect
yet
vaccin
program
challeng
implement
countri
requir
rvspecif
cell
key
longterm
protect
vaccineinduc
protect
depend
cytokin
product
direct
kill
infect
cell
cell
countermeasur
crucial
helper
celledevelop
anerg
state
may
assist
develop
vaccin
confer
longterm
protect
exanthem
widespread
erupt
skin
rash
may
associ
fever
system
symptom
infecti
agent
caus
exanthem
identifi
cherri
record
case
combin
fever
widespread
rash
pediatr
popul
caus
viral
infect
rel
result
bacteri
infect
goodyear
laidler
price
kenni
harper
correct
diagnosi
skin
manifest
result
direct
inocul
infecti
agent
onto
cutan
surfac
dissemin
distant
site
main
research
theme
viral
exanthem
infect
mani
viral
ie
paravir
exanthem
benign
resolv
spontan
other
may
rapidli
lead
fatal
condit
review
drago
et
al
thu
special
attent
diagnos
even
vaccineprevent
viral
exanthem
must
appli
avoid
aris
seriou
complic
nonimmun
pregnant
women
fetus
harm
class
virus
caus
exanthem
white
et
al
common
exanthemat
infect
typic
caus
transmiss
virus
persontoperson
except
alphavirus
mosquito
vector
multitud
virus
caus
agent
includ
rubeola
viru
rubella
viru
human
parvoviru
human
herpesviru
hhv
type
varicellazost
viru
vzv
variola
alphavirus
molluscum
contagiosum
viru
tabl
numer
exanthemat
disord
caus
virus
cover
section
includ
ebola
zika
becom
classifi
emerg
viral
exanthem
due
increas
number
atrisk
popul
critic
need
classifi
diseas
minim
outbreak
risk
pregnant
women
fetus
keighley
et
al
rubeola
measl
viru
mev
belong
morbilliviru
genu
paramyxovirida
famili
negativesens
rna
viru
nonseg
genom
lipid
envelop
measur
nm
diamet
review
griffin
et
al
kb
genom
encod
eight
protein
viral
envelop
compos
hemagglutinin
h
fusion
f
gp
project
matrix
protein
line
interior
helic
nucleocapsid
compos
rna
nucleocapsid
n
protein
pack
within
envelop
coil
phosphoprotein
p
larg
polymeras
l
protein
attach
two
ns
protein
c
v
regul
cellular
respons
infect
modul
ifn
signal
bellini
et
al
human
natur
host
highli
contagi
mev
viru
spread
respiratori
rout
despit
avail
safe
efficaci
vaccin
measl
remain
one
import
virus
caus
child
morbid
mortal
worldwid
moss
griffin
wolfson
et
al
infect
mev
associ
mortal
rate
african
children
grai
et
al
nandi
et
al
unvaccin
refuge
camp
virusna
popul
mortal
moss
shank
et
al
femal
mortal
domin
featur
disord
result
infect
garenn
mani
acut
mortal
secondari
infect
result
immun
suppress
induc
mev
also
observ
beckford
et
al
mev
persist
long
latenc
infect
period
often
result
develop
subacut
scleros
panenceph
sspe
male
caus
fatal
neurolog
diseas
present
mani
year
follow
origin
infect
bellini
et
al
adapt
cellular
immun
respons
gener
regard
import
clearanc
mev
children
low
plasma
ig
may
recov
mev
infect
defect
cellular
immun
develop
progress
infect
albertyn
et
al
mcquaid
et
al
mevspecif
antibodi
cell
respons
coincid
onset
rash
wherebi
rash
biopsi
mevrepl
infect
epitheli
cell
high
level
cell
infiltr
polack
et
al
cell
subset
appear
particularli
import
control
clearanc
infecti
mev
expand
circul
virusspecif
ctl
found
blood
patient
suffer
rash
increas
cell
also
found
mevinduc
pneumonia
jay
et
al
mongkolsapaya
et
al
myou
et
al
addit
depend
target
tissu
cell
type
analyz
regard
mev
infect
though
differenti
rate
cytotox
ifn
product
implic
key
effector
mechan
mev
clearanc
patterson
et
al
stubblefield
park
et
al
fink
et
al
specif
combin
cell
cell
b
cell
record
requir
control
primari
mev
infect
tishon
et
al
protect
measl
base
mevspecif
humor
antibodybas
immun
diagnost
current
gold
standard
protect
via
quantif
neutral
antibodi
viral
hemagglutinin
h
fusion
f
surfac
gp
bouch
et
al
haralambieva
et
al
plotkin
mev
howev
trigger
aggress
immun
respons
involv
humor
cellular
arm
immun
system
moss
griffin
de
vri
et
al
buchanan
bonthiu
measl
clear
memori
cell
provid
lifelong
immun
reinfect
mev
bester
importantli
mev
infect
immun
reaction
pathogen
suppress
week
year
lead
risk
suscept
secondari
infect
believ
driver
complic
mortal
long
measl
clear
convers
measlesinduc
immun
amnesia
sometim
disabl
immun
memori
year
suggest
work
toward
herd
protect
infect
support
associ
measl
vaccin
lower
mortal
rate
childhood
infect
mina
et
al
occasion
spontan
tumor
regress
also
observ
occur
natur
measl
infect
suggest
mev
infect
may
adopt
gener
safe
effect
oncolyt
virus
russel
peng
rubella
viru
belong
togavirida
famili
sole
member
rubiviru
genu
rubella
contain
singlestrand
positivesens
rna
genom
frey
viral
particl
measur
nm
diamet
oshiro
et
al
pleomorph
nucleocapsid
surround
hostderiv
lipid
membran
battisti
et
al
rubella
protein
spike
anchor
extern
layer
membran
membranebound
protein
bridg
row
protein
consid
main
immunodomin
antigen
respons
control
receptormedi
endocytosi
petruzziello
et
al
katow
sugiura
antibodi
level
neutral
domain
correl
protect
rubella
viru
mitchel
et
al
cordoba
et
al
wilson
et
al
rubella
viru
spread
persontoperson
via
respiratori
rout
caus
agent
rubella
diseas
commonli
known
german
measl
lambert
et
al
although
rarer
unit
state
rubella
infect
remain
major
health
concern
develop
countri
tosh
et
al
although
acquir
rubella
infect
sever
adult
transplacent
transfer
viru
develop
fetu
matern
viremia
caus
devast
consequ
congenit
rubella
syndrom
cr
watson
et
al
infant
worldwid
born
cr
year
common
cr
symptom
includ
spontan
abort
prematur
deliveri
fetal
death
ocular
abnorm
neurolog
problem
abnorm
cardiac
develop
deaf
white
et
al
congenit
malform
due
cr
may
present
birth
condit
diabet
mellitu
deaf
intellectu
disabl
andor
subacut
enceph
may
develop
month
year
later
watson
et
al
white
et
al
mass
immun
program
number
rubella
case
progress
declin
longer
endem
unit
state
remain
endem
countri
dramat
increas
report
case
last
decad
reef
et
al
recent
africa
asian
seen
increas
rubella
case
repres
signific
proport
global
case
report
neither
region
immun
polici
place
control
rubella
outbreak
white
et
al
recent
rubella
epidem
japan
report
case
least
cr
case
minakami
et
al
also
serv
demonstr
partial
vaccin
strategi
lead
major
outbreak
case
vaccin
provid
young
women
outbreak
affect
adult
male
populationsda
phenomenon
also
observ
countri
appli
vaccin
strategi
paradowskastankiewicz
et
al
janta
et
al
measl
clear
memori
cell
provid
lifelong
immun
mev
bester
distinct
pattern
cellular
immun
rubella
viru
observ
relat
time
elaps
follow
vaccin
lambert
et
al
predomin
biomark
earli
cellular
measl
immun
character
immunosuppress
phenotyp
increas
tnfa
decreas
ifng
prolif
properti
circul
peripher
lymphocyt
pukhalski
et
al
late
immun
shift
predominantli
proinflammatori
cytokin
profil
via
increas
concentr
granulocytemacrophag
colonystimul
factor
tnfa
combin
decreas
dhiman
et
al
human
leukocyt
antigen
hla
known
play
critic
role
immun
respons
virus
contribut
heterogen
immun
respons
rubella
viru
result
polymorph
natur
wherebi
hla
class
ii
polymorph
restrict
avail
repertoir
rubella
antigen
present
cell
therefor
influenc
subsequ
immun
respons
mitchel
et
al
ou
et
al
ou
et
al
current
effort
place
deciph
immunogenet
antirubella
humor
cellmedi
immun
respons
focu
better
understand
hla
polymorph
toward
develop
vaccin
candid
util
construct
compris
hlaspecif
epitop
induc
immun
across
heterogenet
popul
review
lambert
et
al
natur
infect
vaccin
induc
humor
cellular
immun
respons
confer
protect
rubella
tosh
et
al
humor
respons
convent
use
measur
record
protect
immun
human
popul
cellular
immun
respons
intrins
humor
immun
bautistalopez
et
al
horstmann
et
al
ovsyannikova
et
al
nepom
et
al
vesikari
et
al
akaboshi
et
al
farzaneh
et
al
sinc
induct
healthcar
system
immun
live
attenu
rubella
viru
vaccin
demonstr
safe
effect
prevent
infect
cr
interrupt
endem
rubella
transmiss
lambert
et
al
live
attenu
rubella
vaccin
strain
proven
track
record
safeti
immunogen
efficaci
hilleman
et
al
plotkin
singl
dose
demonstr
potent
induc
humor
immun
lifelong
protect
infect
vaccin
also
demonstr
boost
previous
immun
person
diazortega
et
al
safeti
efficaci
use
recombin
rubella
vector
also
test
toward
enhanc
immun
respons
siv
hiv
epitop
increas
memori
b
cell
repertoir
observ
upon
reexposur
rubella
vector
virnik
et
al
durabl
hivspecif
cellular
immun
observ
rubella
vector
boost
cytotox
antigenspecif
respons
central
effector
memori
cell
subset
rosati
et
al
vzv
also
known
viru
varicelloviru
genu
herpesvirida
famili
human
vector
hambleton
specif
infect
cell
epitheli
cell
ganglia
gershon
et
al
vzv
virus
diamet
measur
nm
encod
linear
doublestrand
dna
genom
consist
approxim
kb
encod
least
uniqu
gene
except
homolog
herp
simplex
viru
cohen
vzv
virion
compos
viral
dna
capsid
tegument
surround
capsid
envelop
surround
tegument
incorpor
major
viral
gp
arvin
lytic
infect
phase
vzv
produc
least
gp
express
virion
human
cell
surfac
process
common
herpesvirus
gene
express
believ
proceed
orderli
cascad
immedi
earli
gene
earli
gene
late
gene
latent
vzv
infect
gene
express
restrict
reactiv
addit
round
lytic
infect
gershon
gershon
vzv
extraordinarili
high
transmiss
rate
highli
communic
via
airborn
transmiss
rout
concentr
viru
come
vesicl
shed
skin
lesion
lead
cellfre
contagi
airborn
virus
evidenc
fact
infect
children
without
skin
lesion
contagi
tsolia
et
al
chen
et
al
primari
vzv
infect
caus
varicella
also
commonli
known
chickenpox
cellular
immun
vzv
wane
elderli
immunocompromis
popul
latent
vzv
becom
reactiv
caus
zoster
ie
shingl
herp
zoster
usual
associ
chronic
pain
also
numer
seriou
neurolog
ocular
disord
well
multipl
viscer
gastrointestin
disord
includ
ulcer
hepat
pancreat
gershon
et
al
gilden
et
al
avail
antivir
drug
vaccin
varicella
zoster
safe
effect
treatment
prevent
strategi
gershon
gershon
varicella
global
endem
transmit
yearround
frequent
epidem
occur
everi
year
outbreak
commonli
occur
nurseri
school
hospit
medic
institut
refuge
camp
militari
correct
facil
izurieta
et
al
levi
et
al
longfield
et
al
although
often
selflimit
diseas
varicella
also
result
death
develop
countri
estim
patient
hospit
seriou
complic
three
death
per
patient
galil
et
al
rawson
et
al
complic
varicella
requir
hospit
includ
bacteri
superinfect
skin
blood
bone
lung
well
enceph
hemorrhag
manifest
pediatr
immunocompromis
popul
gershon
et
al
importantli
acquir
vzv
earli
pregnanc
often
result
sever
congenit
defect
newborn
ender
vzv
great
exampl
success
herd
vaccin
program
children
dramat
influenc
epidemiolog
caus
declin
hospit
case
unit
state
gershon
et
al
follow
transmiss
respiratori
mucosa
vzv
prolifer
oral
pharynx
infect
human
tonsillar
activ
memori
cell
induc
tissuehom
properti
sen
et
al
vzv
propag
cellerich
region
lymph
node
rapid
prolifer
dissemin
circul
infect
dermi
epidermi
organ
ku
et
al
ku
et
al
lymphopenia
typic
observ
patient
viral
incub
follow
increas
leukocyt
count
correl
onset
rash
resolut
viremia
infect
vzv
recov
pbmc
children
exhibit
rash
ozaki
et
al
koropchak
et
al
sawyer
et
al
extens
observ
thymic
lymphocyt
levin
observ
cell
subset
examin
moffat
et
al
though
innat
skin
immun
caus
delay
multipl
skinbound
vzv
adapt
immun
system
mount
attack
howev
aggress
vzv
replic
skin
result
characterist
varicella
rash
ku
et
al
high
vzv
titreskin
vesicl
rash
provid
cellfre
viru
persontoperson
transmiss
chen
et
al
vzv
also
latent
infect
neuron
cranial
nerv
ganglia
dorsal
root
ganglia
enter
autonom
ganglia
gershon
gershon
vzv
reactiv
caus
ganglia
becom
necrot
hemorrhag
head
et
al
vzv
protein
found
neuron
nonneuron
cell
vzvinduc
ganglion
often
also
mark
upregul
mhc
class
ii
protein
associ
infiltr
cell
schmidbauer
et
al
steain
et
al
gowrishankar
et
al
vzv
vaccin
becam
avail
approxim
infect
adult
later
develop
shingl
yawn
et
al
singl
dose
lyophil
live
attenu
vzv
vaccin
ie
zoster
vaccin
live
zvl
zostavax
merck
indic
prevent
latent
vzv
reactiv
lead
shingl
individu
older
year
zvl
licens
countri
million
distribut
dose
global
willi
et
al
associ
efficaci
rate
age
test
oxman
et
al
schmader
et
al
consist
origin
clinic
trial
dataset
tseng
et
al
langan
et
al
marin
et
al
howev
increas
vzv
suscept
arisen
due
increas
age
popul
immunesuppress
organ
transplant
recipi
chemotherapi
patient
hivinfect
individu
suffer
chronic
ill
forb
et
al
patient
earlier
exposur
exogen
vzv
protect
shingl
boost
cellular
immun
arvin
et
al
thoma
et
al
memori
immun
respons
follow
natur
acquir
primari
vzv
infect
character
vzv
igg
iga
antibodi
well
vzvspecif
cell
vzvspecif
igg
antibodi
bind
mani
vzv
protein
mediat
viru
neutral
antibodydepend
cytotox
review
arvin
frequenc
vzvspecif
memori
prolifer
cell
estim
approxim
one
pbmc
hayward
et
al
vsvspecif
memori
cytotox
mhc
class
ior
class
iirestrict
cell
produc
ifng
tnfa
recogn
vzv
ge
gb
gc
gh
gi
protein
found
persist
year
varicella
exposur
jenkin
et
al
huang
et
al
asanuma
et
al
diaz
et
al
hayward
et
al
sharp
et
al
sadzotdelvaux
et
al
abil
live
attenu
varicella
vaccin
elicit
vzvspecif
igg
cell
immun
naiv
host
establish
prelicens
clinic
evalu
gershon
et
al
expect
design
magnitud
vzvspecif
immun
respons
correl
infecti
viru
content
antigen
content
individu
vaccin
formul
bergen
et
al
watson
et
al
importantli
later
discov
provid
two
dose
children
result
higher
igg
antibodi
titr
increas
cell
prolifer
experiment
evid
suggest
memori
respons
sustain
effect
regimen
watson
observ
led
recent
recommend
implement
twodos
regimen
varicella
vaccin
vaccin
recipi
arvin
studi
regimen
affect
longterm
protect
adapt
cell
immun
respons
vaccin
exemplifi
vzv
vaccin
studi
potenti
modifi
dosag
timelin
maxim
overal
persist
benefici
longterm
effect
vaccin
mani
virus
histor
smallpox
sever
human
diseas
caus
variola
viru
varv
highli
lethal
highli
contagi
prior
erad
human
popul
moor
et
al
varv
belong
genu
orthopoxviru
famili
poxvirida
also
includ
zoonot
speci
vaccinia
viru
vacv
monkeypox
viru
cowpox
viru
camelpox
viru
shchelkunov
orthopoxvirus
envelop
brickshap
virus
measur
nm
contain
doublestrand
dna
genom
encod
gene
measur
approxim
kb
garon
et
al
unlik
dna
virus
replic
viru
factori
cytoplasm
infect
cell
pauli
et
al
varv
encod
approxim
protein
found
termin
region
genom
associ
host
immun
evas
origin
smallpox
unknown
varv
consid
one
deadli
diseas
human
histori
decim
popul
extent
significantli
alter
cours
human
civil
smallpox
believ
first
appear
bc
africa
oldest
credibl
confirm
found
sanskrit
write
bc
smallpox
lesion
believ
observ
mummifi
egyptian
ruler
rams
v
bc
ristanov
et
al
prior
erad
varv
circul
human
popul
mani
centuri
repeatedli
caus
largescal
epidem
centuri
instanc
smallpox
caus
death
european
per
year
babkin
babkina
smith
mcfadden
despit
varv
erad
human
popul
two
decad
ago
fear
potenti
reemerg
threat
use
potenti
bioterror
agent
subsid
led
numer
debat
concern
destruct
exist
viral
stock
current
maintain
unit
state
russia
destruct
stock
postpon
benefit
research
elucid
varv
mechan
pathogenesi
toward
design
therapeut
well
efficaci
vaccin
strategi
may
requir
potenti
futur
outbreak
smith
mcfadden
stone
immuneevas
mechan
varv
least
understood
among
orthopoxvirus
due
difficulti
find
appropri
host
anim
model
turner
moyer
along
limit
avail
authent
variola
protein
sinc
erad
massung
et
al
thu
two
variola
protein
name
smallpox
inhibitor
complement
enzym
spice
vaccinia
viru
complement
control
protein
vcp
character
similar
structur
dunlop
et
al
viral
antigen
regul
human
complement
system
yadav
et
al
import
stimul
innat
immun
also
import
featur
adapt
immun
shown
bolster
antivir
cell
respons
includ
ifn
cytokin
express
nori
remuzzi
moss
shisler
vacv
use
extens
human
immun
vaccin
employ
provid
crossprotect
varv
toward
smallpox
erad
jacob
et
al
first
gener
vacvvarv
vaccin
produc
dryvax
apsv
lancyevaxina
livp
contain
live
vacv
induc
robust
humor
immun
character
high
antibodi
titer
neutral
opson
viral
particl
fix
complement
hemagglutin
antibodydepend
cell
cytotox
amanna
et
al
panchanathan
et
al
vaccin
sinc
observ
gener
adapt
immun
respons
mani
concentr
frey
et
al
rock
et
al
includ
secret
effector
cytokin
eg
ifng
lyse
infect
cell
amanna
et
al
hammarlund
et
al
secondgener
vaccin
creat
biodefens
contain
replic
compet
virus
artenstein
grabenstein
compar
efficaci
dryvax
thirdgener
vaccin
formul
use
attenu
vacv
strain
mva
nyvac
dvvl
increas
safeti
profil
artenstein
kennedi
et
al
proof
adapt
cellular
immun
essenti
prevent
spread
varv
follow
immun
gener
overal
protect
immun
smallpox
come
observ
individu
celledefici
disord
suffer
seriou
sometim
fatal
infect
vaccin
agammaglobulinem
children
risk
advers
complic
rock
et
al
varv
vaccin
induc
strong
cell
respons
peak
immun
contract
provid
stabl
memori
cell
popul
remain
detect
decad
amanna
et
al
hammarlund
et
al
memori
cell
persist
longest
amara
et
al
defect
cellular
immun
lead
uncontrol
vaccinia
infect
lane
et
al
cell
abl
prevent
mortal
b
celledefici
anim
infect
vacv
belyakov
et
al
cell
protect
overal
effect
xu
et
al
essenti
optim
ctl
function
memori
format
sun
bevan
kennedi
et
al
vacvspecif
cell
recogn
divers
array
viral
protein
cell
epitop
predominantli
found
earli
nonstructur
gene
transcript
factor
terajima
et
al
cell
epitop
late
viral
product
includ
membran
structur
protein
replic
enzym
jing
et
al
linkag
b
cell
cell
epitop
varv
protein
suggest
helper
celleb
cell
interact
requir
gener
robust
vacvspecif
antibodi
respons
sett
et
al
human
varvspecif
cell
observ
persist
year
follow
immun
rock
et
al
exanthem
disord
virus
repres
case
combin
fever
widespread
rash
pediatr
popul
correct
diagnosi
especi
critic
distinguish
benign
versu
lethal
viral
strain
variat
caus
lifelong
morbid
children
born
infect
mother
mev
transmit
via
human
respiratori
rout
despit
vaccin
avail
still
caus
african
children
mortal
sever
risk
sspederiv
fatal
year
later
survivor
histor
common
mani
virus
gold
standard
diagnost
protect
made
quantif
humor
neutral
antibodi
adapt
cellular
immun
respons
howev
critic
mev
clearanc
mevspecif
cell
respons
coincid
rash
dens
infiltr
cell
combin
cell
cell
b
cell
control
primari
infect
cell
domin
control
clearanc
memori
cell
abl
provid
lifelong
protect
mev
infect
induc
gener
longterm
immunosuppress
lead
vulner
pathogen
caus
secondari
infect
immunosuppress
believ
simultan
confer
herd
protect
observ
induc
spontan
tumor
regress
rubella
viru
infect
progress
declin
immun
program
continu
endem
mani
countri
result
complet
absenc
problemat
partial
vaccin
program
still
caus
sever
cr
case
infant
worldwid
per
year
humor
respons
convent
use
measur
protect
immun
adapt
immun
confer
protect
natur
infect
vaccin
induc
humor
cellular
immun
respons
memori
cell
provid
lifelong
immun
presenc
cytolyt
cell
biomark
vaccineinduc
immunogen
vaccin
develop
compris
hlaspecif
epitop
induc
immun
across
heterogenet
popul
sinc
rubella
vaccin
boost
previous
immun
vector
investig
use
toward
immun
program
unrel
virus
vzv
extraordinarili
high
human
transmiss
rate
primari
vzv
infect
caus
varicella
vaccin
program
initi
would
reemerg
declin
adapt
immun
caus
zoster
immunocompromis
popul
caus
hospit
everi
death
three
per
patient
vzv
repres
poster
child
herd
vaccin
program
led
declin
hospit
event
vzv
infect
rate
rise
immunocompromis
immunesuppress
popul
infect
human
tonsillar
activ
memori
cell
home
lymph
infect
cell
follow
lymphopenia
resolv
rash
onset
innat
immun
control
vzv
spread
adapt
immun
develop
fulli
counter
infect
vsvspecif
memori
ctl
persist
year
varicella
exposur
observ
increas
cell
prolifer
bettersustain
memori
respons
result
multipl
booster
dose
vaccin
caus
modif
vaccin
program
smallpox
varv
one
deadli
diseas
human
histori
caus
european
casualti
annual
prior
vaccinemedi
erad
viral
stock
maintain
necess
develop
new
vaccin
counter
potenti
futur
reemerg
varv
naturalor
bioterrorismderiv
sourc
character
variola
protein
amplifi
strengthen
cell
respons
firstgener
vacv
vaccin
induc
robust
humor
immun
adcc
addit
gener
adapt
immun
respons
mark
cytokin
cell
lysi
varv
vaccin
induc
strong
initi
effector
cell
respons
b
cell
linkag
contact
gener
stabl
memori
popul
varvspecif
cell
persist
year
accordingli
secondand
thirdgener
vaccin
creat
biodefens
design
stimul
adapt
cellular
immun
global
liver
cancer
fifth
common
cancer
averag
case
per
year
repres
cancer
mortal
rate
reflect
geograph
incid
rate
almost
liver
cancer
occur
develop
countri
individu
affect
diseas
hepatocellular
carcinoma
hcc
common
form
liver
cancer
approxim
case
associ
chronic
infect
hepat
b
viru
hbv
hepat
c
viru
hcv
elserag
hepat
virus
name
display
hepatotrop
preferenti
infect
hepatocyt
caus
liver
inflamm
also
known
viral
hepat
infect
hbv
hcv
promot
liver
cirrhosi
affect
lead
develop
hcc
patient
fattovich
et
al
approxim
global
popul
million
peopl
chronic
infect
hbv
strong
correl
hbv
preval
hcc
incid
mortal
chronic
hbv
infect
account
approxim
hcc
case
adult
hcc
case
children
elserag
hepat
transmiss
persontoperson
contact
infect
blood
bodi
secret
fecalor
rout
involv
least
five
specif
virus
name
hepat
b
c
e
virus
tabl
infecti
viral
hepat
import
challeng
health
worldwid
hepat
viru
hav
hepat
e
viru
hev
acut
endem
mani
lowincom
countri
usual
caus
selflimit
hepat
wherea
hbc
hcv
also
caus
acut
ill
usual
lead
chronic
progress
liver
fibrosi
cirrhosi
increas
risk
hcc
stanaway
et
al
hbv
control
adult
chronic
persist
neonat
infect
shin
et
al
hepat
virus
differ
virolog
hbv
envelop
dna
viru
belong
hepadnavirida
famili
contain
bp
partial
doublestrand
relaxedcircular
dna
genom
revers
transcrib
via
pregenom
rna
intermedi
encod
four
overlap
open
read
frame
translat
produc
viral
core
protein
surfac
protein
revers
transcriptas
hbx
nguyen
et
al
transmiss
hbv
result
exposur
infecti
blood
bodi
fluid
contain
blood
hbv
integr
human
genom
contribut
genom
instabl
ultim
hcc
zhao
et
al
hcv
also
transmit
infect
blood
unlik
hbv
hcv
integr
host
genom
hcv
also
positivestrand
rna
viru
classifi
hepaciviru
genu
within
flavivirida
famili
genom
kb
length
includ
intern
ribosom
entri
site
encod
structur
ns
protein
structur
protein
form
viral
particl
includ
core
protein
envelop
gp
ns
protein
includ
ion
channel
proteas
serin
proteas
rna
helicas
polypeptid
protein
rnadepend
rna
polymeras
moradpour
et
al
hepat
viru
hdv
also
transmit
contact
infect
blood
bodi
fluid
hdv
envelop
neg
sens
singlestrand
close
circular
rna
viru
requir
hbv
coinfect
propag
infect
virus
commonli
result
sever
liver
patholog
hdv
genom
rna
hdv
compos
approxim
bp
packag
approxim
molecul
hepat
delta
antigen
form
viral
particl
hdv
envelop
surround
genom
hdag
protein
compos
three
hbv
small
medium
larg
hbv
hbsag
envelop
protein
hdv
also
encod
replicas
polymeras
rather
util
host
cellular
machineri
replic
abba
afzal
hav
hev
positivestrand
nonenvelop
rna
virus
transmit
via
fecalor
rout
unlik
chronic
persist
hbv
hcv
typic
clear
acut
infect
immunocompet
individu
park
rehermann
hav
hepatotrop
viru
belong
hepatoviru
genu
within
picornavirida
famili
genom
consist
approxim
bp
encompass
singl
open
read
frame
code
singl
polyprotein
posttransl
process
structur
ns
protein
structur
protein
hav
divid
polypeptid
form
icosahedr
capsid
viru
ns
protein
involv
rna
replic
viral
polyprotein
process
martin
lemon
hev
famili
hepevirida
genu
orthohepeviru
kb
genom
three
open
read
frame
encod
viral
replicas
capsid
protein
small
phosphoprotein
requir
secret
viral
particl
debe
et
al
hav
hev
waterborn
virus
usual
caus
acut
hepat
without
progress
chronic
liver
diseas
joon
et
al
annual
million
case
hav
million
case
hev
infect
record
global
makialamandanda
et
al
hev
outbreak
report
africa
nearli
everi
year
involv
case
kim
et
al
hav
highli
endem
africa
infect
children
confer
longterm
immun
reduc
seriou
epidem
jacobsen
hbv
hcv
hdv
sexual
parenter
vertic
transmit
usual
evolv
chronic
hepat
liver
cirrhosi
hcc
caus
high
morbid
mortal
rate
global
million
peopl
chronic
infect
hbv
million
hcv
million
hdv
kramvi
kew
hugh
et
al
thursz
fontanet
superinfect
hbv
patient
hdv
frequent
acceler
progress
hbv
diseas
liver
cirrhosi
consider
increas
burden
chronic
liver
diseas
hugh
et
al
hav
hbv
hcv
respons
major
viral
hepat
case
similar
differ
immun
respons
infect
three
virus
possibl
explain
distinct
diseas
cours
outcom
hepat
viru
infect
shin
et
al
type
iii
ifn
major
compon
antivir
innat
immun
system
induc
express
ifnstimul
gene
isg
observ
much
highli
induc
hcv
hav
hbv
indic
viru
recogn
innat
immun
system
su
et
al
lanford
et
al
wieland
et
al
anoth
compon
innat
immun
system
nk
cell
also
believ
respons
protect
hcv
increas
nk
cell
protect
individu
coincid
increas
ifng
cytotox
shin
et
al
though
virusspecif
antibodi
produc
viral
hepat
infect
differ
role
accord
hepat
viru
infect
havspecif
antibodi
virusneutr
activ
induc
natur
infect
vaccin
immun
confer
lifelong
protect
immun
walker
et
al
martin
lemon
hbv
surfac
antigen
hbsagspecif
antibodi
induc
infect
immun
recombin
protein
virusneutr
activ
confer
protect
immun
guidotti
chisari
hcvspecif
antibodi
produc
infect
offer
longterm
protect
persist
subject
loss
neutral
activ
viru
mutat
ineffect
celltocel
hcv
transmiss
takaki
et
al
dowd
et
al
timp
et
al
cell
play
critic
role
acut
hcv
hbv
infect
robust
multipl
epitopespecif
cell
respons
assist
cell
spontan
resolut
infect
shin
et
al
support
observ
deplet
cell
chimpanze
delay
rapid
clearanc
recoveri
infect
virus
grakoui
et
al
thimm
et
al
hcv
hbv
infect
becom
chronic
persist
virusspecif
cell
becom
exhaust
function
impair
acut
hcv
infect
virusspecif
cell
detect
blood
liver
week
postinfect
appear
coincid
larg
declin
viru
titr
shin
et
al
shin
et
al
hbv
virusespecif
cell
respons
also
import
spontan
resolut
hbv
infect
respons
observ
vigor
broad
polyclon
patient
resolv
primari
infect
absenc
associ
prolong
infect
delay
viral
clearanc
chisari
et
al
thimm
et
al
cell
also
play
import
role
hav
infect
observ
target
multipl
epitop
hav
despit
recent
result
suggest
hav
control
virusspecif
cell
cell
walker
et
al
shin
et
al
final
hepat
viru
infect
result
liver
injuri
directli
caus
virus
rather
immunemedi
mechan
guidotti
chisari
liver
injuri
biomark
correl
acut
hav
hab
hac
infect
guidotti
chisari
park
rehermann
walker
et
al
may
result
cytotox
activ
cell
believ
induc
apoptosi
hepatocyt
close
proxim
target
cell
guidotti
chisari
produc
cell
recruit
nonspecif
mononuclear
cell
hbvspecif
cytokin
secret
cell
iannacon
et
al
shin
et
al
effect
vaccin
control
hav
hbv
avail
decad
hev
vaccin
also
licens
use
china
sinc
zhu
et
al
stanaway
et
al
neonat
hbv
vaccin
proven
highli
effect
induc
protect
antibodi
prevent
perinat
horizont
transmiss
hbv
lee
et
al
howev
observ
hbsagspecif
ifngor
pbmc
absent
mani
adolesc
suggest
booster
vaccin
administ
provid
continu
hbv
immun
lu
et
al
hav
vaccin
provid
longterm
immun
gener
popul
immunocompromis
patient
infect
hiv
crumcianflon
et
al
exist
vaccin
hcv
despit
ongo
effort
toward
design
test
abil
gener
prolong
cellular
humor
immun
respons
review
naderi
et
al
absenc
vaccin
progress
hcv
treatment
includ
oral
treatment
achiev
cure
patient
includ
previous
consid
difficult
treat
case
poordad
et
al
lawitz
et
al
liver
cancer
fifth
common
cancer
repres
cancer
annual
case
mortal
occur
hcc
common
liver
cancer
case
result
chronic
infect
hbv
hcv
signific
million
chronic
infect
respect
contrast
hav
hev
caus
acut
hepat
progress
chronic
liver
diseas
hdv
infect
depend
preexist
hbv
infect
hcv
induc
express
type
iii
isg
nk
cell
present
hbv
infect
unrecogn
innat
immun
virusspecif
antibodi
produc
viral
hepat
infect
differ
role
across
infect
robust
multipl
epitopespecif
cell
respons
domin
depend
assist
cell
resolut
acut
hav
hbv
hcv
infect
chronic
infect
cytolyt
cell
either
caus
extens
liver
injuri
hepatocyt
andor
becom
toler
function
impair
effect
vaccin
control
hav
hbv
provid
protect
antibodi
hav
vaccin
provid
longterm
immun
immunocompromis
booster
vaccin
program
requir
persist
hbv
immun
vaccin
licens
highli
variabl
rapidli
mutat
hcv
despit
numer
ongo
effort
gener
provid
robust
cellular
humor
immun
respons
histor
central
nervou
system
cn
consid
immunolog
privileg
site
within
bodi
bailey
et
al
galea
et
al
engelhardt
prendergast
anderton
definit
immunolog
privileg
site
also
includ
brain
cornea
testi
pregnant
uteru
reduc
delay
abil
reject
foreign
tissu
graft
compar
convent
site
within
bodi
skin
streilein
bailey
et
al
carson
et
al
mrass
wening
kaplan
niederkorn
though
cn
protect
highli
complex
barrier
system
wide
varieti
virus
still
manag
gain
access
induc
diseas
due
size
tissu
penetr
strategi
number
cn
viral
infect
outweigh
bacteri
fungal
protozoa
cn
infect
combin
romero
newland
follow
cn
infect
inflammatori
event
aris
distinct
anatom
region
mening
mening
brain
enceph
spinal
cord
myeliti
also
simultan
aris
multipl
region
meningoenceph
encephalomyel
mani
neurotrop
virus
viral
cytopatholog
play
major
role
cn
dysfunct
review
swanson
mcgavern
viru
breach
protect
barrier
cn
mani
way
main
rout
mechan
via
blood
inhal
ingest
virus
move
past
mucosa
establish
infect
secondari
lymphoid
tissu
later
shed
circul
blood
caus
broad
system
infect
swanson
mcgavern
cn
parenchyma
protect
plethora
agent
carri
circul
via
elabor
network
call
bloodbrain
barrier
bbb
bloodcerebrospin
fluid
barrier
ransohoff
et
al
virus
evolv
adapt
overcom
barrier
mcgavern
kang
virus
infect
vascular
endotheli
cell
permit
direct
passag
across
bbb
cn
verma
et
al
mose
et
al
coyn
et
al
addit
part
cn
complet
protect
bbb
permit
rapid
entri
sever
virus
van
den
pol
et
al
wolinski
et
al
infect
hematopoiet
cell
circul
blood
also
serv
trojan
hors
transport
undetect
viru
cn
clay
et
al
taborgodwin
et
al
mechan
includ
system
viral
infect
lead
massiv
system
inflamm
ensu
bbb
breakdown
open
floodgat
cn
infect
varieti
otherwis
restrict
infecti
agent
arsenionun
et
al
eugenin
et
al
recogn
distinct
viru
strain
caus
human
neurolog
diseas
major
document
case
caus
virus
transmit
human
bloodeat
arthropod
vector
also
known
arbovirus
mainli
transmit
mosquito
tick
includ
poliovirus
pv
alphavirus
mosquitoborn
flavivirus
tickborn
orthobunyavirus
mosquitoborn
mammarenavirus
rabi
viru
rabv
tabl
pv
caus
agent
poliomyel
commonli
refer
polio
human
enteroviru
member
famili
picornavirida
typic
spheric
nonenvelop
picornavirus
rang
diamet
nm
positivestrand
rna
nucleotid
translat
polyprotein
ie
polioviru
yield
protein
upon
cleavag
viral
proteas
picornaviru
replic
occur
cytoplasm
infect
cell
associ
intracellular
membran
virion
releas
cell
lysi
ultim
kill
cell
caus
extens
damag
tissu
host
immun
respons
picornavirus
includ
cytokin
releas
antibodi
product
ctl
activ
review
dotzauer
kraemer
viral
genom
pv
singlestrand
rna
approxim
nucleotid
enclos
nonenvelop
capsid
compris
copi
four
differ
polypeptid
arrang
icosahedr
symmetri
racaniello
three
pv
serotyp
caus
paralyt
diseas
cellular
receptor
three
serotyp
wherebi
pv
interact
express
mani
differ
cell
type
lead
conform
chang
viru
particl
follow
releas
rna
genom
cellular
cytoplasm
mendelsohn
et
al
hogl
cytoplasm
viral
rna
genom
translat
product
new
infecti
virion
begin
pv
infect
result
ingest
viru
replic
oropharyng
intestin
mucosa
sabin
ward
primari
site
multipl
mucosa
pv
viru
drain
cervic
mesenter
lymph
node
blood
caus
transient
viremia
symptom
persontoperson
transmiss
pv
viru
fecalor
rout
pv
shed
fece
major
natur
human
infect
end
stage
modest
symptom
includ
sore
throat
fever
malais
dotzauer
kraemer
howev
pvinfect
individu
viru
gain
entri
cn
neuron
neuromuscular
junction
nmj
replic
motor
neuron
within
spinal
cord
brain
stem
motor
cortex
lead
pvcharacterist
flaccid
muscl
paralysi
disord
poliomyel
racaniello
koyuncu
et
al
approxim
paralyt
case
result
death
roush
et
al
follow
pv
infect
vaccin
neutral
antibodi
gener
clear
viru
detect
mani
year
provid
lifelong
protect
libbey
fujinami
vaccin
inject
inactiv
pv
vaccin
prevent
viral
spread
cn
wherea
vaccin
liveattenu
oral
pv
vaccin
protect
infect
intestin
tract
also
prevent
persontoperson
spread
viru
nathanson
griffin
pv
remain
import
caus
neurolog
diseas
three
liveattenu
vaccin
strain
risk
recombin
genom
revert
virul
form
griffin
pv
endem
afghanistan
pakistan
india
nigeria
polit
reason
part
signific
modal
toward
achiev
pv
erad
via
vaccin
pv
usual
clear
adapt
immun
respons
condit
antibodi
defici
human
howev
continu
fecal
shed
pv
contribut
establish
persist
infect
cycl
martin
nathanson
libbey
fujinami
though
less
known
role
adapt
cell
respons
control
pv
infect
rel
neutral
antibodi
respons
known
pvspecif
cell
induc
vaccin
individu
key
epitop
also
identifi
graham
et
al
simon
et
al
induct
pvspecif
cell
suggest
result
stimul
pvinfect
dc
macrophag
wahid
et
al
dotzauer
kraemer
demonstr
hla
class
ii
present
remain
intact
infect
antigenpres
cell
apc
cytolyt
cell
produc
ifng
lyse
pvinfect
cell
viru
clearanc
pvspecif
cytotox
ifngsecret
cytotox
cell
respons
induc
infect
macrophag
also
document
wahid
et
al
suggest
cytolyt
cell
partak
adapt
immun
reaction
pv
dotzauer
kraemer
approxim
virus
includ
flaviviru
genu
flavivirida
famili
virus
speci
associ
dengu
yellow
fever
yf
japanes
enceph
je
tickborn
enceph
west
nile
enceph
import
arbovirus
caus
extens
global
morbid
mortal
diamond
flavivirus
envelop
virus
singlestrand
rna
genom
translat
cytoplasm
gener
singl
polyprotein
cleav
structur
ns
protein
viru
host
proteas
variou
encod
viral
protein
assembl
gener
capsid
envelop
receptor
bind
membran
fusion
viral
assembl
transmembran
protein
prm
assist
protein
fold
function
entri
flavivirus
target
cell
mediat
interact
e
gp
host
cell
surfac
receptor
pereralecoin
et
al
flavivirus
believ
evad
immun
system
enter
brain
spinal
cord
via
circul
blood
johnson
mim
may
cross
bbb
passiv
transport
across
endothelium
activ
replic
endotheli
cell
trojan
hors
mechan
viru
hide
inflammatori
cell
transit
brain
solomon
vaughn
ifndepend
complement
system
innat
immun
respons
along
humor
neutral
antibodi
protect
viru
dissemin
spread
review
diamond
adapt
cellular
immun
also
import
toward
destruct
infect
cell
wherebi
virusspecif
ctl
becom
activ
prolifer
releas
inflammatori
cytokin
follow
exposur
flavivirusinfect
cell
kesson
et
al
kuran
et
al
liu
et
al
muralikrishna
et
al
also
evid
flaviviru
replic
enhanc
myeloid
cell
observ
dengu
yf
west
nile
tickborn
je
virus
diamond
je
flaviviru
lead
caus
enceph
amplifi
waterfowl
transmit
human
mosquito
vector
possibl
humantohuman
transmiss
erlang
et
al
pediatr
geriatr
popul
higher
risk
infect
je
burchard
et
al
je
infect
remain
asymptomat
je
devast
symptomat
patient
caus
mortal
rate
patient
popul
batchelor
petersen
approxim
day
je
incub
patient
suffer
high
fever
chill
headach
myalgia
confus
pediatr
patient
also
symptom
gastrointestin
pain
vomit
seizur
postj
infect
handicap
persist
neurolog
deficit
last
lifetim
survivor
treatment
je
method
prevent
avoid
mosquito
vaccin
batchelor
petersen
four
avail
je
vaccin
regist
worldwid
use
nation
immun
program
differ
age
group
includ
inactiv
vero
cell
cultur
vaccin
jevc
ixiaro
inactiv
mous
brain
deriv
vaccin
jemb
cell
cultureederiv
primari
hamster
kidney
liveattenu
vaccin
base
sa
strain
manufactur
china
liveattenu
chimer
vaccin
base
gene
yf
backbon
combin
vero
cellepropag
sa
strain
imojev
chen
et
al
cell
respons
je
vaccin
report
cell
respons
detect
major
follow
vaccin
crossreact
flavivirus
turtl
et
al
jespecif
cell
respons
observ
pbmc
isol
jeinfect
patient
vaccin
individu
cell
direct
structur
viral
protein
identifi
vaccin
individu
contrast
specif
respons
ns
c
protein
infect
patient
nathanson
cole
find
indic
ns
protein
especi
import
role
initi
cell
respons
main
target
jespecif
cellemedi
immun
respons
addit
cytolyt
cell
clone
crossreact
flavivirus
gener
individu
immun
inactiv
je
vaccin
aihara
et
al
final
cell
believ
primari
determin
protect
je
infect
kumar
et
al
kumar
et
al
virus
alphaviru
genu
member
togavirida
famili
virus
group
envelop
positivesens
rna
virus
mosquitoborn
virus
caus
two
major
type
human
diseas
old
world
alphavirusesdsindbi
chikungunya
ross
river
virusdcaus
arthriti
arthralgia
new
world
alphavirusesdeastern
eeev
western
weev
venezuelan
equin
enceph
viru
veev
dcaus
enceph
trobaugh
klimstra
alphavirus
small
icosahedralshap
envelop
virus
approxim
nm
diamet
size
mancini
et
al
morgan
et
al
fuller
alphaviru
virion
acquir
host
cell
lipid
membran
viral
assembl
fuller
acheson
tamm
vogel
et
al
viral
gp
spike
protrus
arrang
icosahedr
pattern
embed
within
membran
interact
nucleocapsid
fuller
vogel
et
al
owen
kuhn
alphaviru
singlestrand
positivesens
rna
genom
kb
long
consist
two
larg
open
read
frame
encod
ns
structur
polyprotein
subsequ
cleav
viral
host
proteas
creat
four
ns
protein
five
structur
protein
c
strauss
et
al
hardi
strauss
review
leung
et
al
major
concern
new
world
eeev
weev
veev
alphavirus
natur
transmit
mosquito
veev
also
highli
infecti
via
aerosol
rout
zack
paessler
precis
mechan
entri
alphavirus
cn
remain
elus
howev
alphavirus
infect
human
equin
neuron
caus
neurolog
symptom
mild
febril
ill
sever
enceph
result
death
ramakrishna
et
al
zack
paessler
develop
sever
enceph
believ
result
neuron
cell
death
acceler
viral
spread
host
neuroinflammatori
viral
respons
paessler
et
al
paessler
et
al
antibodi
protect
lethal
meningoenceph
viru
transmit
insect
virusspecif
cell
found
import
protect
lethal
meningoenceph
aerosol
transmiss
rout
paessler
et
al
yun
et
al
review
libbey
fujinami
veev
remain
emerg
diseas
threat
natur
transmiss
well
via
usag
biolog
weapon
new
world
alphavirus
veev
import
human
equin
pathogen
caus
outbreak
febril
neurolog
diseas
primarili
latin
america
past
centuri
past
outbreak
last
sever
year
involv
equin
human
case
larg
geograph
region
largest
outbreak
record
central
colombia
saw
human
case
estim
equin
death
recent
outbreak
mexico
south
america
behind
classif
veev
reemerg
diseas
weaver
et
al
veev
also
develop
biolog
weapon
amen
use
warfar
terror
current
global
emphas
biolog
defens
renew
interest
virolog
hawley
eitzen
weaver
et
al
veev
infect
human
typic
caus
nonleth
incapacit
symptom
includ
fever
headach
malais
myalgia
sore
throat
vomit
rarer
case
cn
involv
usual
follow
acut
febril
phase
associ
sever
neurolog
diseas
rang
somnol
mild
confus
seizur
ataxia
paralysi
coma
mortal
rate
rang
high
infect
children
infect
adult
bowen
et
al
veev
also
report
caus
longterm
neurolog
deficit
abort
teratogen
effect
de
la
mont
et
al
riva
et
al
weaver
et
al
like
veev
though
major
human
infect
eeev
asymptomat
cn
involv
result
sever
neurolog
sign
lesion
sequela
estim
associ
human
mortal
rate
neurolog
manifest
includ
facial
edema
paresi
paralysi
respiratori
impair
alter
mental
state
seizur
children
mani
symptom
persist
longterm
surviv
patient
fatal
case
eeev
gross
lesion
brain
includ
edema
mening
congest
hemorrhag
malacia
deresiewicz
et
al
veev
eeev
natur
human
case
weev
typic
show
earli
flulik
ill
associ
fever
malais
headach
similar
eeev
weev
result
cn
involv
signific
proport
case
includ
symptom
somnol
seizur
coma
motor
neuron
dysfunct
nineti
percent
infant
infect
weev
sever
cn
symptom
calish
human
mortal
rate
weev
infect
rang
neurolog
sequela
may
becom
perman
featur
survivor
steel
twenhafel
alphaviru
express
vector
base
sindbi
semliki
forest
veev
demonstr
induc
strong
cell
respons
antigen
rayner
et
al
lundstrom
lundstrom
riezebosbrilman
et
al
schlesing
dubenski
polo
et
al
innat
adapt
immun
respons
control
virus
target
cn
neuron
griffin
viral
disrupt
type
ifn
signal
pathway
interfer
surviv
veev
well
infect
sindbi
west
nile
virus
ryman
et
al
samuel
diamond
white
et
al
virusspecif
antibodi
respons
critic
limit
viral
spread
facilit
clearanc
infecti
viru
neuron
within
brain
levin
et
al
alpha
beta
ab
gamma
delta
gd
cell
respons
demonstr
import
control
veev
paessler
et
al
cell
respons
reduc
mortal
rate
direct
kill
infect
cell
produc
antivir
cytokin
increas
product
virusspecif
antibodi
bilzer
stitz
patterson
et
al
shrestha
et
al
sitati
diamond
veev
replicon
particl
deliv
adjuv
demonstr
induc
activ
cell
respons
thompson
et
al
recent
cell
demonstr
facilit
recoveri
veevinduc
encephalomyel
absenc
antibodi
respons
dramat
reduct
viral
titr
cn
cell
best
cell
produc
ifng
respons
effici
control
veev
cn
lesion
cell
facilit
recoveri
sever
viral
encephalomyel
brook
et
al
commerci
equin
vaccin
market
unit
state
gener
inactiv
produc
viremia
fever
leukopenia
hors
gener
robust
neutral
antibodi
veev
protect
rechalleng
walton
et
al
us
armi
special
immun
program
provid
inactiv
individu
fail
seroconvert
respons
booster
pittman
et
al
howev
neither
vaccin
shown
complet
protect
nonhuman
primat
aerosol
exposur
pratt
et
al
stabli
attenu
veev
vaccin
candid
call
produc
preclin
test
demonstr
safe
immunogen
possibl
superior
pratt
et
al
hart
et
al
ludwig
et
al
adapt
immun
pbmcderiv
biomark
signatur
identifi
abl
effici
stratifi
vaccin
nonrespond
individu
erwin
cohen
et
al
rabv
type
speci
genu
lyssaviru
within
rhabdovirida
famili
rhabdovirus
negativesens
singlestrand
rna
virus
distinct
bulletshap
structur
virus
lyssavirus
potenti
caus
rabi
human
nucleotid
genom
encod
five
protein
nucleoprotein
n
phosphoprotein
p
matrix
glycoprotein
g
rnadependentrna
polymeras
l
marston
et
al
rabv
caus
acut
enceph
mammal
caus
fatal
rate
almost
rabv
commonli
infect
mani
anim
includ
bat
skunk
fox
dog
also
infect
insect
plant
rabv
anim
saliva
spread
host
via
bite
scratch
infect
anim
surviv
year
secret
infecti
particl
saliva
untreat
infect
human
gener
result
rapidli
fatal
acut
myeloenceph
koyuncu
et
al
rabid
dog
import
reservoir
rabv
dog
bite
account
human
infect
rabv
like
member
lyssavirus
neurotrop
infect
peripher
nerv
close
primari
site
bite
rabv
rapidli
move
retrograd
axon
transport
dorsal
root
ganglia
viru
replic
begin
rabv
particl
enter
axon
motor
neuron
nmj
via
bind
nicotin
acetylcholin
receptor
eg
nachr
neural
cell
adhes
molecul
ugolini
transneuron
rabv
spread
occur
synapt
connect
neuron
wherebi
virus
move
postsynapt
presynapt
neuron
human
rel
long
asymptomat
incub
period
initi
rabv
infect
occur
sometim
last
year
provid
time
cn
infect
intervent
howev
death
almost
alway
ensu
rabv
infect
reach
cn
mark
behavior
neurolog
symptom
koyuncu
et
al
rabv
enter
cn
rapidli
move
brain
associ
explos
increas
viru
replic
initi
symptom
includ
pain
paraesthesia
close
bite
site
often
associ
fever
fatigu
weak
associ
limb
nonspecif
neurolog
symptom
includ
headach
anxieti
occur
day
prior
acut
enceph
morrison
wenzel
current
avail
therapi
diseas
symptom
develop
death
ensu
within
number
day
follow
cnsassoci
symptom
jackson
et
al
review
johnson
et
al
rabv
replic
begin
follow
cn
penetr
therebi
limit
earlier
possibl
detect
lowlevel
primari
antigen
peripher
circul
delay
antigen
present
antigen
later
rapidli
drain
cn
local
lymphoid
tissu
knopf
et
al
b
cell
stimul
next
delay
obstacl
reentri
cn
experiment
model
demonstr
b
cell
infiltr
dorsal
root
ganglia
spinal
cord
brain
johnson
et
al
cell
major
immun
subset
cnsinfiltr
cell
fasmedi
apoptot
phenotyp
baloul
lafon
intrins
complex
immun
respons
present
cn
includ
tight
mhc
express
regul
irwin
et
al
express
immunosuppress
factor
neuron
cell
addit
bbb
remain
intact
rabv
infect
roy
et
al
numer
studi
suggest
viru
suppress
adapt
immun
respons
believ
part
due
deficit
adapt
immun
effector
cell
accumul
within
cn
due
viral
induc
reduct
bbb
permeabl
libbey
fujinami
roy
et
al
two
rabv
vaccin
licens
human
applic
human
diploid
cell
vaccin
manufactur
aventi
pasteur
purifi
chick
embryo
cell
vaccin
manufactur
chiron
preexposur
vaccin
given
healthcar
personnel
laboratori
worker
travel
endem
area
caus
detect
igm
igg
antibodi
within
week
follow
exposur
longterm
studi
provid
evid
igg
antibodi
provid
effect
protect
rabv
due
abil
penetr
tissu
contrast
igm
penetr
tissu
turner
multifacet
approach
human
rabi
erad
involv
govern
support
diseas
awar
vaccin
atrisk
human
dog
requir
achiev
goal
world
health
organ
erad
rabi
fook
et
al
cn
immunolog
privileg
protect
highli
complex
barrier
system
virus
evolv
overcom
barrier
caus
cn
infect
greatli
outnumb
bacteri
fungal
protozoa
infect
combin
ingest
pv
multipli
oropharyng
intestin
mucosa
drain
cervic
mesenter
lymph
node
blood
ahead
penetr
cn
caus
polio
case
result
death
neutral
antibodi
adapt
immun
system
clear
pv
infect
may
provid
lifelong
protect
vaccin
combin
induc
pvspecif
cytolyt
cell
viru
clearanc
coadministr
pose
risk
revers
virul
recombin
je
flaviviru
amplifi
waterfowl
transmit
human
mosquito
infect
asymptomat
mortal
rate
infect
individu
caus
associ
disord
leav
survivor
lifetim
associ
morbid
exist
je
treatment
prevent
involv
either
avoid
mosquito
vaccin
flavivirus
evad
immun
system
cross
bbb
inflammatori
cell
mediat
trojan
hors
mechan
je
dissemin
limit
innat
immun
respons
neutral
antibodi
produc
humor
immun
virusspecif
ctl
je
vaccin
licens
worldwid
major
vaccin
individu
circul
jespecif
cell
crossreact
flavivirus
alphavirus
transmit
mosquito
bite
infect
neuron
caus
mild
sever
enceph
result
death
past
outbreak
number
hundr
thousand
veev
infect
caus
mortal
children
involv
cn
penetr
caus
sever
longterm
neurolog
disord
veev
natur
emerg
diseas
threat
also
highli
develop
biolog
weapon
amen
warfar
terror
due
aerosol
transmiss
rout
associ
lethal
meningoenceph
ifn
signal
pathway
ab
gd
cell
respons
innat
adapt
immun
control
veev
target
cn
virusspecif
antibodi
respons
critic
limit
viral
spread
absenc
antibodi
veev
replicon
particl
induc
cell
respons
abl
induc
recoveri
veevinduc
encephalomyel
cytotox
cell
control
veev
cn
lesion
veev
vaccin
induc
robust
neutral
antibodi
protect
rechalleng
vaccin
respond
circul
pbmc
biomark
militari
program
give
booster
fail
seroconvert
contrast
virus
rabv
replic
begin
cn
penetr
facilit
depth
bite
canin
vector
therebi
limit
possibl
detect
primari
viral
antigen
peripheri
result
delay
minim
innat
humor
respons
rabvrel
acut
enceph
symptom
begin
fatal
sure
follow
due
absenc
cn
infiltr
adapt
immun
effector
cell
result
virusinduc
decreas
bbb
permeabl
countermeasur
protect
tight
mhc
express
regul
apoptot
phenotyp
bbbinfiltr
cell
rabv
vaccin
caus
increas
ig
littl
known
concern
vaccineassoci
adapt
immun
respons
viral
hemorrhag
fever
vhf
classif
origin
studi
hantavir
hemorrhag
fever
hf
later
extend
includ
crimeanecongo
hf
omsk
hf
vhf
result
infect
envelop
rna
virus
four
famili
flavivirida
filovirida
arenavirida
bunyavirida
vhf
design
given
sever
febril
ill
abnorm
vascular
regul
vascular
damag
peter
zaki
vascular
dysregul
occur
earli
cours
diseas
visibl
skin
flush
hypotens
conjunctiv
vasodil
wherebi
vascular
damag
capillari
leakag
occur
diseas
progress
caus
edema
serou
effus
pleural
periton
caviti
termin
phase
vhf
shock
aris
increas
diseas
sever
combin
vascular
dysregul
damag
capillari
leakag
paessler
walker
detail
mechan
hemorrhag
plasma
leakag
vhf
includ
endotheli
injuri
activ
mononuclear
phagocyt
system
cytokin
storm
platelet
aggreg
consumpt
activ
coagul
cascad
insuffici
coagul
factor
sever
hepat
damag
schnittler
feldmann
chen
cosgriff
mechan
vari
among
diseas
cell
organ
tropism
caus
virus
host
respons
paessler
walker
flavivirus
filovirus
arenavirus
bunyavirus
main
caus
hf
tabl
virus
continu
propag
part
life
cycl
primat
bat
rodent
farm
anim
mosquito
tick
infect
virus
caus
mild
vascular
instabl
fatal
shock
hemorrhag
rang
unnotic
lifethreaten
pathogen
mechan
hfv
divers
includ
hepat
necrosi
lead
deregul
coagul
factor
cytokin
storm
increas
permeabl
complement
activ
overal
diseas
sever
virus
vari
wherebi
ebola
marburg
hf
caus
high
fatal
rate
wherea
yf
dengu
infect
asymptomat
sever
vhf
commonli
correl
ineffect
immun
high
viral
load
sever
plasma
leakag
occur
viral
clearanc
fever
break
dengu
hf
dhf
approxim
virus
includ
flaviviru
genu
flavivirida
famili
virus
speci
associ
dengu
yf
je
tickborn
enceph
west
nile
enceph
import
arbovirus
caus
extens
global
morbid
mortal
diamond
flavivirus
envelop
virus
singlestrand
rna
genom
translat
cytoplasm
gener
singl
polyprotein
cleav
structur
ns
protein
viru
host
proteas
variou
encod
viral
protein
includ
capsid
envelop
receptor
bind
membran
fusion
viral
assembl
transmembran
protein
prm
assist
protein
fold
function
although
precis
mechan
unclear
flavivirus
believ
evad
immun
system
enter
brain
spinal
cord
via
circul
blood
johnson
mim
may
cross
bbb
passiv
transport
across
endothelium
activ
replic
endotheli
cell
trojan
hors
mechan
util
inflammatori
cell
solomon
vaughn
ifndepend
complement
system
innat
immun
respons
humor
immun
produc
neutral
antibodi
limit
dissemin
infect
protect
viral
spread
review
diamond
cellular
immun
also
import
toward
erad
infect
cell
wherebi
infect
induc
recognit
flavivirusinfect
cell
virusspecif
ctl
becom
activ
prolifer
releas
inflammatori
cytokin
kesson
et
al
kuran
et
al
liu
et
al
muralikrishna
et
al
howev
also
evid
flaviviru
replic
enhanc
myeloid
cell
observ
dengu
yf
west
nile
tickborn
je
virus
diamond
yf
viru
yfv
import
histor
current
one
global
fear
diseas
terror
africa
europ
america
hundr
thousand
kill
america
spandcrippl
economi
watson
klimstra
yfv
member
genu
flaviviru
flavivirida
famili
contain
singlestrand
rna
genom
approxim
kb
yfv
virion
icosahedr
compos
nucleocapsid
compos
capsid
c
protein
subunit
surround
lipid
bilay
deriv
host
membran
viral
envelop
stud
dimer
envelop
e
membran
protein
total
diamet
approxim
nm
major
compon
virion
surfac
e
protein
respons
cellsurfac
receptor
bind
virion
assembl
fusion
immunogen
viral
protein
encod
singl
open
read
frame
produc
polyprotein
later
process
proteolyt
cleavag
structur
c
e
ns
protein
review
gardner
ryman
yfv
infect
viru
transmit
bite
infect
aed
aegypti
mosquito
found
urban
area
infect
patient
often
develop
sever
acut
ill
hemorrhag
yf
diseas
associ
symptom
fever
nausea
vomit
epigastr
pain
hepat
jaundic
renal
failur
hemorrhag
shock
case
result
death
watson
klimstra
yf
prototyp
vhf
share
mani
pathophysiolog
featur
viral
disord
associ
via
similar
syndrom
except
yf
caus
sever
symptom
hepat
dysfunct
monath
vasconcelo
yfv
remain
endem
south
american
african
countri
monkey
reservoir
caus
regular
outbreak
jungl
yf
result
mani
infect
per
year
caus
death
million
risk
infect
africa
vaccin
preval
low
outbreak
angola
serv
exampl
yfv
travelerassoci
spread
neighbor
countri
reach
far
china
viru
watson
klimstra
repres
prime
popul
major
outbreak
epic
proport
wasserman
et
al
geograph
shift
mosquito
popul
north
america
also
creat
new
risk
yfv
dengu
zika
infect
popul
monaghan
et
al
despit
avail
vaccin
yfv
sinc
larg
epidem
still
arisen
dramat
surg
yfv
africa
late
report
case
recent
outbreak
also
affect
brazil
paraguay
argentina
uganda
sudan
ethiopia
immun
critic
reduc
elimin
viral
infect
contribut
factor
viru
amplif
multifactori
elus
includ
emerg
new
viral
strain
prolong
period
hot
humid
weather
promot
insect
propag
review
monath
vasconcelo
fiftyseven
million
peopl
vaccin
yf
across
africa
five
hundr
million
dose
liveattenu
yf
vaccin
repres
effect
vaccin
ever
creat
distribut
last
year
monath
vasconcelo
humor
cellular
immun
elicit
observ
well
character
neutral
antibodi
provid
protect
also
provid
robust
longliv
polyfunct
adapt
cell
immun
respons
watson
klimstra
neutral
antibodi
remain
accept
correl
protect
yfv
greater
immun
individu
develop
neutral
antibodi
gotuzzo
et
al
also
elicit
complex
modul
innat
immun
cytokin
elev
level
plasma
ifng
day
postvaccin
neve
et
al
restimul
innat
immun
cell
cultur
nk
cell
neutrophil
monocyt
vaccin
human
yf
antigen
result
increas
product
ifng
tnfa
neve
et
al
gardner
ryman
luizasilva
et
al
silva
et
al
sinc
develop
humor
immun
gold
standard
gener
vaccin
develop
studi
aspect
human
immun
howev
recent
studi
adapt
cellemedi
immun
demonstr
cell
strongli
respond
activ
cell
detect
day
vaccin
cell
detect
sever
day
later
kohler
et
al
blom
et
al
increas
cell
prolifer
correl
directli
level
viru
genom
plasma
peak
viru
elimin
cell
clone
respond
differenti
central
memori
effector
memori
subpopul
dewitt
et
al
still
detect
year
follow
vaccin
wieten
et
al
cell
respond
epitop
contain
everi
protein
product
gener
polyprotein
upon
peptid
restimul
cell
activ
cytotox
profil
includ
increas
express
ifng
tnfa
granzym
b
blom
et
al
akondi
et
al
exhaust
retain
longliv
memori
polyfunct
phenotyp
least
year
follow
rechalleng
akondi
et
al
dengu
viru
denv
also
member
singlestrand
positivesens
rna
virus
flavivirida
famili
caus
viscer
cn
diseas
human
close
relat
yfv
denv
fever
often
mistaken
yfv
infect
far
seriou
dhf
addit
symptom
develop
includ
hemorrhag
shock
mortal
rate
exceed
left
untreat
roger
et
al
denv
spheric
virion
compris
three
structur
protein
capsid
c
premembran
membran
prm
envelop
e
e
protein
direct
sever
critic
step
viral
replic
cycl
includ
engag
cellular
attach
entri
factor
membran
fusion
virion
assembl
denv
bind
target
cell
via
glycosaminoglycan
ctype
lectin
dcsign
mannos
receptor
immunomodulatori
protein
tim
tam
receptor
diamond
pierson
thu
target
denv
infect
includ
monocyt
macrophag
dc
mast
cell
possibl
hepatocyt
endotheli
cell
follow
entri
cellular
cytoplasm
viral
genom
kb
rna
translat
singl
polyprotein
later
cleav
three
structur
seven
ns
protein
viral
host
cell
proteas
twentyf
percent
denv
infect
caus
mild
symptom
includ
dengu
fever
df
sever
lethal
dhf
caus
shock
via
hemorrhag
capillari
leak
syndrom
df
character
abrupt
onset
febril
ill
caus
headach
sever
muscl
joint
pain
rash
wherea
dhf
character
rapid
onset
capillari
leakag
accompani
signific
thrombocytopenia
liver
injuri
halstead
yf
denv
origin
believ
sylvat
viru
natur
life
cycl
involv
multipl
mosquito
vertebr
speci
asia
africa
diallo
et
al
denv
adapt
human
demographi
via
mosquito
vector
aed
aegypti
breed
urban
area
trpi
hausermann
case
denv
infect
increas
sinc
estim
million
case
df
case
dhf
occur
global
everi
year
cure
denvassoci
disord
vaccin
develop
complic
antibodydepend
enhanc
futur
heterotyp
infect
induc
vaccin
vaughn
halstead
deen
thu
avoid
control
aed
aegypti
best
approach
limit
denv
infect
roger
et
al
adapt
immun
cell
vigor
frequent
recogn
denv
protein
wherea
capsid
envelop
protein
domin
target
cell
simmon
et
al
duangchinda
et
al
weiskopf
et
al
weiskopf
et
al
rivino
et
al
cell
believ
contribut
protect
denv
denvspecif
cell
prolifer
produc
ifng
lyse
target
cell
primari
denv
infect
kuran
et
al
mathew
et
al
gagnon
et
al
livingston
et
al
higher
frequenc
denvspecif
ifngproduc
cell
present
children
asymptomat
denv
infect
hatch
et
al
cell
contribut
protect
denv
challeng
yauch
et
al
yauch
et
al
zompi
et
al
zellweg
et
al
hla
allel
associ
increas
risk
denv
sever
correl
weak
cell
respons
vice
versa
impli
protect
role
cell
sever
denv
diseas
human
weiskopf
et
al
first
dengu
vaccin
dengvaxia
licens
asian
south
american
countri
protect
four
denv
serotyp
demonstr
good
safeti
efficaci
clinic
trial
recent
withdrawn
philippin
due
caus
elev
diseas
sever
administ
follow
infect
wichmann
et
al
suggest
failur
liveattenu
tetraval
dengueeyf
chimer
viru
vaccin
guy
et
al
result
lack
ns
protein
otherwis
dominantli
target
cell
simmon
et
al
duangchinda
et
al
weiskopf
et
al
weiskopf
et
al
rivino
et
al
make
critic
accur
assess
antibodi
respons
rather
cell
respons
context
denv
vaccin
develop
weiskopf
sett
lassa
viru
lasv
caus
lassa
fever
lf
envelop
viru
two
singlestrand
rna
segment
anoth
viru
caus
hf
lasv
old
world
member
arenavirida
famili
virus
singlestrand
arenaviru
genom
consist
small
larg
l
rna
segment
measur
kb
respect
larg
segment
encod
small
zincbind
z
protein
regul
transcript
replic
viral
bud
along
rna
polymeras
l
small
segment
encod
np
two
envelop
glycoprotein
respons
cell
entri
review
russier
et
al
lasv
disord
endem
africa
neighbor
countri
safronetz
et
al
gunther
et
al
though
infect
rate
difficult
quantifi
due
limit
survey
infrastructur
classif
clinic
symptom
common
diseas
lasv
predict
respons
approxim
infect
result
death
year
ogbu
et
al
mccormick
et
al
transmiss
human
via
rodent
host
mastomi
natalensi
mccormick
et
al
apc
dc
macrophag
believ
first
cell
target
lasv
infect
baiz
et
al
mahanti
et
al
rapidli
speed
dissemin
lasv
multisystem
organ
due
widespread
physiolog
distribut
mucos
tissu
skin
due
eas
motil
across
variou
organ
tissu
apc
believ
respons
spread
lasv
establish
system
infect
hensley
et
al
apc
infect
result
substanti
viru
releas
secondari
lymphoid
organ
liver
hepatocyt
fibroblast
endotheli
cell
subsequ
infect
lymphopenia
cell
nk
cell
b
cell
observ
earli
diseas
onset
review
russier
et
al
lasv
infect
sever
rang
asymptomat
infect
fatal
hf
fisherhoch
et
al
commonli
result
viral
infect
nonspecif
symptom
begin
sever
day
infect
includ
fever
headach
arthralgia
myalgia
sever
asthenia
earli
symptom
typic
follow
sever
symptom
pharyng
conjunct
cough
abdomin
pain
diarrhea
vomit
sever
affect
patient
cervic
facial
edema
hemorrhag
renal
liver
failur
encephalopathi
occur
death
follow
system
shock
edington
white
survivor
lasvrel
disord
persist
lifelong
morbid
disabl
condit
includ
deaf
cummin
et
al
vaccin
licens
lasv
ribavirin
exist
treatment
effect
administ
earli
infect
avail
broad
distribut
countri
lasv
endem
mccormick
et
al
cell
play
crucial
role
outcom
sever
lasv
infect
associ
defect
cell
respons
sinc
cell
respons
stimul
cell
antigen
respons
infect
viru
howev
cell
respons
demonstr
play
critic
role
control
lasv
strong
memori
cell
respons
direct
lasv
np
gp
protein
observ
lasvseroposit
healthi
individu
endem
region
ter
meulen
et
al
high
serum
concentr
chemokin
attract
activ
cell
associ
nonfat
lasv
infect
christensen
et
al
dufour
et
al
vice
versa
fatal
case
mahanti
et
al
control
acut
lf
correl
increas
circul
activ
cell
respons
lasv
infect
antigen
baiz
et
al
vaccin
studi
protect
lethal
lasv
rechalleng
associ
induct
cell
immun
fisherhoch
et
al
geisbert
et
al
howev
comparison
virus
lasvinfect
dc
unabl
mount
effector
cell
respons
panneti
et
al
human
nonhuman
primat
studi
demonstr
lasv
np
gp
protein
main
viral
antigen
recogn
activ
cell
meulen
et
al
ter
meulen
et
al
fisherhoch
et
al
fisherhoch
mccormick
geisbert
et
al
suggest
vaccin
use
protein
induc
longterm
memori
cell
expans
best
control
spread
lf
ebola
viru
ebov
caus
rapidli
fatal
hf
current
treatment
muyembetamfum
et
al
team
et
al
ebov
member
filovirida
famili
filament
negativestrand
rna
virus
caus
sever
human
diseas
filovirus
virus
variabl
long
filament
measur
nm
diamet
reach
length
nm
mani
turn
branch
tendenc
curv
resembl
number
virus
compos
nucleocapsid
matrix
envelop
protein
wherebi
seven
gene
encod
np
viral
protein
l
polymeras
gp
hoenen
et
al
express
regul
viru
product
releas
mohan
et
al
np
emb
genom
complex
rna
synthesi
protein
local
viru
matrix
space
watanab
et
al
hoenen
et
al
ebov
transmit
human
via
mucos
surfac
skin
injuri
vertic
transmiss
feldmann
geisbert
except
cell
infect
almost
human
cell
use
variou
differ
attach
mechan
review
falasca
et
al
innat
adapt
immun
respons
involv
ebov
pathogenesi
innat
immun
deregul
involv
inhibit
typei
ifn
respons
perturb
cytokin
signal
along
impair
dc
nk
cell
adapt
immun
deregul
involv
humor
cellmedi
immun
falasca
et
al
high
level
ebov
replic
associ
multipl
cell
type
associ
system
dissemin
result
highli
complex
pathogenesi
model
includ
detriment
immun
suppress
hyperactiv
lead
disord
coagul
tissu
damag
absenc
treatment
result
rapid
multipl
organ
failur
death
within
day
symptomat
infect
basel
et
al
year
ebov
relat
filovirus
repeatedli
reemerg
caus
larg
epidem
highli
fatal
hf
ongo
ebov
outbreak
africa
brought
viru
forefront
research
report
case
infect
associ
death
mcelroy
et
al
natur
serolog
respons
ebov
infect
involv
virusspecif
igm
igg
antibodi
respons
sometim
detect
earli
usual
later
symptom
begin
row
et
al
ebovinfect
dc
impair
cytokin
product
requir
cell
activ
mahanti
et
al
wherea
infect
macrophag
unabl
matur
bosio
et
al
ebov
classifi
immunosuppress
viru
sinc
numer
protein
interfer
immun
respons
induc
cell
apoptosi
lymphopenia
absenc
antibodi
respons
fatal
case
basler
amarasingh
classif
ebovtarget
mechan
compromis
lack
infrastructur
adequ
biosafeti
contain
level
facil
requir
analyz
deadli
viru
howev
observ
adapt
cell
immun
respons
shown
ebov
correl
fatal
outcom
caus
aberr
cytokin
respons
baiz
et
al
baiz
et
al
wauquier
et
al
villing
et
al
ansari
decreas
cell
increas
apoptot
cell
phenotyp
baiz
et
al
wauquier
et
al
geisbert
et
al
bradfut
et
al
gupta
et
al
recent
work
ebov
induc
increas
cell
activ
viral
np
cell
demonstr
largest
increas
express
activ
prolifer
biomark
sustain
activ
follow
ebov
clearanc
follow
patient
discharg
suggest
continu
antigen
stimul
resolut
diseas
mcelroy
et
al
recent
rvsvzebov
recombin
replicationecompet
vesicular
stomat
virusebas
vaccin
express
surfac
gp
zair
ebolaviru
demonstr
efficaci
prevent
ebov
diseas
contact
contact
contact
recent
confirm
case
guinea
west
africa
henaorestrepo
vaccin
produc
rapid
innat
immun
respons
singl
dose
suggest
lead
longerterm
full
protect
provid
essenti
period
restrict
viru
replic
develop
specif
adapt
respons
marzi
crimeancongo
hemorrhag
fever
viru
cchfv
tickborn
viru
caus
hf
result
human
fatal
cchfv
member
nairovirida
famili
virus
genu
orthonairoviru
order
bunyavirida
virus
singlestrand
negativesens
rna
genom
possess
three
segment
larg
l
medium
small
segment
casal
clerx
et
al
l
segment
encod
viral
rnadepend
rna
polymeras
respons
mrna
synthesi
rna
replic
honig
et
al
msegment
encod
numer
ns
two
structur
gp
gn
gc
respons
cell
tropism
attach
target
neutral
antibodi
ssegment
encod
viral
np
bind
rna
segment
toward
format
ribonucleoprotein
complex
altamura
et
al
sanchez
et
al
though
hf
cchfv
infect
human
among
common
viral
disord
report
remain
import
fatal
case
bent
et
al
goedhal
et
al
transmiss
cchfv
human
occur
contact
infect
anim
blood
tick
belong
genu
hyalomma
primari
vector
provid
transit
one
infect
human
anoth
mousavijazi
et
al
cchfv
human
infect
involv
sudden
onset
acut
symptom
includ
high
fever
headach
myalgia
petechi
rash
follow
hemorrhag
progress
multiorgan
failur
leukopenia
thrombocytopenia
elev
liver
enzym
hallmark
overal
disord
begum
et
al
sanchez
et
al
outbreakassoci
fatal
rate
vari
reach
mousavijazi
et
al
current
licens
vaccin
use
ribavirin
treatment
investig
remain
controversi
begum
et
al
bent
et
al
distribut
cchfv
infect
associ
diseas
follow
geograph
spread
princip
vector
bent
et
al
whitehous
clinic
cchfv
disord
describ
africa
asia
middl
east
eastern
europ
recent
emerg
countri
includ
turkey
india
spain
greec
almost
case
report
turkey
maltez
et
al
papa
et
al
leblebicioglu
et
al
typic
transient
igm
igg
antibodi
respons
develop
within
day
follow
primari
cchfv
infect
persist
longterm
shepherd
et
al
burt
et
al
lack
thereof
usual
result
fatal
shepherd
et
al
igm
igg
antibodi
howev
correl
clearanc
viral
load
outcom
duh
et
al
impli
innat
cell
immun
must
critic
viral
clearanc
neutral
antibodi
also
caus
protect
nonneutr
antibodi
may
assist
antibodydepend
cellmedi
cytotox
bertolotticiarlet
et
al
thu
immun
correl
protect
cchfv
well
document
vaccin
design
aim
target
cchfv
np
gp
inactiv
vaccin
avail
even
though
attain
immunogen
requir
administr
multipl
dose
demonstr
reduc
infect
induc
neutral
antibodi
respons
cell
respons
np
peptid
mousavijazi
et
al
anoth
promis
approach
use
modifi
vacv
ankara
recombin
vaccin
express
viral
gp
induc
cellular
humor
respons
observ
provid
protect
lethal
diseas
mice
buttigieg
et
al
dowal
et
al
although
cell
respons
known
play
role
protect
clearanc
viral
infect
recent
specif
cell
epitop
gn
gc
shown
stimul
ifng
product
wherebi
respons
detect
sever
year
acut
cchfv
infect
even
absenc
continu
antigen
stimul
ifngproduc
cell
confirm
respons
provid
longterm
protect
goedhal
et
al
vhf
caus
high
fatal
rate
commonli
correl
ineffect
immun
high
viral
load
yfv
import
histor
current
reason
histor
crippl
economi
famili
kill
hundr
thousand
year
yfv
transmit
mosquito
urban
area
caus
mani
infect
death
annual
like
mosquito
vector
virus
yfv
exist
reemerg
threat
due
increas
geolog
spread
world
travel
shift
mosquito
breed
geographi
flavivirus
evad
immun
enter
brain
spinal
cord
via
circul
blood
cross
bbb
via
trojan
hors
mechan
dissemin
infect
protect
yfv
elicit
ifnsign
complement
system
innat
humor
adapt
immun
respons
neutral
antibodi
still
gold
standard
correl
protect
evid
robust
longliv
polyfunct
adapt
cell
immun
respons
provid
earli
vaccin
million
dose
effect
yf
vaccin
distribut
global
importantli
nonexhaust
polyfunct
central
memori
effector
memori
cell
subset
detect
year
follow
vaccin
far
seriou
dhf
infect
denv
contribut
either
mild
sever
hf
mortal
rate
exceed
untreat
yfv
denv
use
mosquito
adapt
urban
area
vector
fifti
million
case
df
case
dhf
occur
global
year
avail
cure
associ
disord
vaccin
develop
complic
antibodydepend
vaccineinduc
enhanc
futur
heterotyp
infect
cytotox
cell
howev
vigor
frequent
recogn
denv
protein
believ
contribut
protect
primari
infect
denv
vaccin
dengvaxia
recent
withdrawn
failur
posit
result
lack
denv
protein
specif
target
cell
demonstr
essenti
accur
assess
cell
respons
context
denv
develop
lasv
also
caus
mild
sever
vhf
may
caus
infect
death
year
lasv
transmit
human
rodent
vector
first
target
apc
dc
macrophag
contribut
rapid
multisystem
organ
lasv
dissemin
due
widespread
physiolog
distribut
lasv
also
caus
lymphopenia
cell
nk
cell
b
cell
survivor
lasvrel
disord
expect
maintain
lifelong
morbid
licens
lasv
vaccin
yet
complic
fact
cell
respons
stimul
cell
antigen
respons
infect
viru
howev
control
acut
lf
correl
increas
circul
strong
memori
cell
respons
lasv
infect
rechalleng
lasv
antigen
ebov
also
caus
mass
hf
infect
almost
human
cell
except
lymphocyt
known
treatment
despit
document
involv
innat
adapt
immun
respons
classif
ebov
target
mechan
compromis
lack
infrastructur
adequ
biosafeti
contain
level
facil
ebov
caus
dc
impair
cytokin
product
cell
activ
inhibit
macrophag
matur
thu
classifi
immunosuppress
viru
fatal
correl
induct
lymphopenia
absenc
antibodi
respons
ebov
howev
caus
increas
cell
activ
record
persist
activ
cell
survivor
knowledg
cell
respons
ebov
np
use
design
effici
target
vaccin
cchfv
also
caus
hf
yield
fatal
case
current
vaccin
cchfv
recent
reemerg
countri
respons
geograph
reloc
primari
tick
vector
infect
cchfv
caus
transient
ig
antibodi
respons
invers
correl
sure
fatal
correl
clearanc
viral
load
outcom
protect
grant
neutral
antibodi
either
impli
innat
cell
arm
immun
critic
viral
clearanc
littl
immun
correl
protect
cchfv
vaccin
design
aim
target
cchfv
np
gp
immunogen
requir
administr
multipl
dose
induc
neutral
antibodi
respons
cell
respons
recent
specif
cell
epitop
cchfv
protein
confirm
stimul
cytotox
cell
provid
protect
survivor
despit
mani
document
instanc
viru
erad
popul
earlier
vaccin
strategi
continu
immin
risk
outbreak
pandem
proport
exist
emerg
virus
result
antivaccin
campaign
unforeseen
viral
strain
recombin
exposur
popul
virus
infect
world
travel
rapidli
grow
age
immunocompromis
world
popul
act
bioterror
use
virus
biolog
weapon
war
past
strategi
develop
certain
vaccin
often
lucki
efficaci
due
elicit
humor
longlast
adapt
cell
immun
wherea
other
fail
induc
shorter
live
humor
respons
alway
confer
longlast
protect
precis
like
overlap
mechan
dictat
lifelong
immun
confer
success
vaccin
smallpox
measl
mump
rubella
polio
yf
complet
understood
becom
clear
howev
innat
immun
usual
prime
adapt
immun
confer
longterm
protect
lack
exist
immunemonitor
methodolog
rather
perhap
lack
correct
implement
continu
analysi
vaccin
individu
hamper
gain
import
knowledg
therefor
seem
urgent
need
standard
vaccin
methodolog
adequ
measur
effector
memori
cell
respons
hostimmun
evas
mechan
appropri
anim
model
human
use
multiparametr
immunemonitor
platform
abl
simultan
document
numer
immun
cell
phenotyp
across
time
postexposur
vaccin
rechalleng
import
global
develop
standard
procedur
biospecimen
bank
vaccin
individu
underst
provid
unpreced
statist
power
analysi
balanc
innat
adapt
immun
arm
confer
lifelong
resist
infect
standard
methodolog
better
assist
futur
ration
design
vaccin
boost
confid
toward
mass
product
stockpil
critic
prophylact
measur
otherwis
crippl
lethal
viral
disord
fink
brinckmann
ug
ter
meulen
v
liebert
ug
gamma
interferon
major
mediat
antivir
defens
experiment
measl
virusinduc
enceph
j
virol
fisherhoch
sp
mccormick
jb
toward
human
lassa
fever
vaccin
rev
med
virol
fisherhoch
sp
mccormick
jb
lassa
fever
vaccin
expert
rev
vaccin
fisherhoch
sp
tomori
nasidi
perezoronoz
gi
fakil
hutwagn
l
mccormick
jb
review
case
nosocomi
lassa
fever
nigeria
high
price
poor
medic
practic
bmj
fisherhoch
sp
hutwagn
l
brown
b
mccormick
jb
effect
vaccin
lassa
fever
j
virol
